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CHAPTER 1 
INTRODUCTION
15
Hormone replacement therapy (HRT) is widely accepted as an effective treatment for 
symptoms associated with the menopause. Many of the preparations are licensed and 
recommended as prophylaxis or treatment for postmenopausal osteoporosis [1 ]. HRT 
may also have a role in the prophylaxis of car diovascular disease this remains 
controversial. Epidemiological studies suggest a reduction in coronary heart disease of 
around 50% in postmenopausal women taking oestrogen [2]. There is confusion amongst 
the medical profession over the prescribing of HRT since many cautions are included in 
the product literature. These include the use in women with diabetes. Women with 
diabetes may have more to gain from their use of HRT than women without.
1.1 Type 2 Diabetes Mellitus
1.1.1 Insulin Resistance
Insulin resistance is the underlying mechanism behind type 2 diabetes mellitus (type2 
DM). This may be defined as a reduced biological response to a physiological amount of 
insulin. There is a broad range of insulin sensitivity in an apparently healthy population. 
Up to 25% of the population may have levels of insulin resistance equal to that seen in 
patients with type 2 diabetes [3]. When a non-diabetic person consumes excessive 
calories and gains weight the body becomes markedly resistant to the actions of insulin. 
Insulin resistance initially results in lower levels of uptake of glucose from the blood into 
the target organs, predominantly skeletal muscle and to a lesser extent adipose tissue [4]. 
This leads to hyperglycaemia. The response to this is for more insulin to be secreted 
from the pancreatic (3 cells resulting in relative hyperinsulinaemia. In the majority of 
people with diabetes in the early or pre diagnosis state this elevation in secretion of 
insulin will ensure that euglycaemia is maintained as tissue insensitivity is overcome.
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Eventually pancreatic p cell failure begins and the hyperinsulinaemic state becomes 
inadequate to maintain euglycaemia and hyperglycaemia ensues. At this point patients 
are classified as suffering from type 2 diabetes.
The association between hypertension, hypertriglyceridaemia, low HDL-cholesterol and 
high LDL-cholesterol is well-established [5]. The “insulin resistance syndrome”, 
“multiple metabolic syndrome”, “Reaven’s syndrome” or “Syndrome X” includes these 
factors and insulin resistance or type 2 diabetes and clotting abnormalities i.e. increased 
fibrinogen and plasminogen activator inhibitor-1. Visceral obesity, hyperuricaemia, 
impaired fibrinolysis and microalbuminuria have also been added to the original 
description of the syndrome.
The most important peripheral tissue in glucose homeostasis, in quantitative terms, is 
skeletal muscle. Anything which affects the insulin sensitivity of skeletal muscle will 
have a profound effect on glucose homeostasis of the whole body [6]. Adipose tissue 
also plays a very important role in glucose homeostasis as it has a pivotal role in the 
integration of carbohydrate and lipid metabolism and hence energy supplies.
The prevalence of insulin resistance can be seen to vary between populations, gender, 
and different age groups and also depends upon the metabolic variables used to define the 
syndrome. Impaired actions of insulin i.e. insulin resistance may result from 2 
mechanisms. Firstly the defect may be at the receptor level. A reduced number of insulin 
receptors are present or a reduction in the receptor’s affinity for insulin. This may occur 
as a consequence of chronic hyperinsulinaemia i.e. down regulation. Secondly there may 
be post-receptor defects. These are defects in intracellular events distal to the binding 
site. This accounts for the majority of insulin resistance seen in type 2 diabetes. These 
defects appear to be species, tissue and or disease dependent [7].
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Insulin resistance is influenced by both genetic and environmental factors. Although it is 
largely associated with obesity especially abdominal obesity [8] it can develop in lean 
individuals [9]. With the euglycaemic insulin clamp technique [10] it has been shown 
that tissue sensitivity to insulin declines by approximately 30-40% when an individual 
becomes greater than 35-40% over ideal body weight [11] [12] [13] [14].
It is clear that a substantial proportion of the population exist with a state of insulin 
resistance, which is compatible with developing diabetes but also increases the risk of 
developing coronary heart disease (CHD). The current view is that there is an inherited 
(or acquired) predisposition present in certain individuals from which various 
components of the metabolic syndrome can emerge. The existence of this predilection 
allows for the clustering of the elements of the syndrome in some individuals but also for 
the dissociation of the elements seen in others. In young individuals obesity, type 2 DM, 
hypertension and atherosclerotic cardiovascular disease are uncommon. By the age of 70 
over 50% of individuals have evidence of CVD and 45-50% are obese and hypertensive. 
The incidence of type 2 DM is somewhat lower (10-12%) although in certain populations 
it is much higher [15].
Most obese individuals have normal glucose tolerance as their insulin resistance is 
matched by increased insulin secretion. The mechanism for this enhanced insulin 
secretion, especially in cases where plasma glucose concentrations were not elevated, 
was initially thought to be a consequence of exposure of the liver to elevated free fatty 
acid (FFA) levels generated by enlarged intra-abdominal fat stores [16]. The levels of 
FFA’s are increased in most obese individuals primarily because of an increase in 
lipolysis in the expanded fat cell mass [17]. Elevated FFA concentrations produce 
peripheral and hepatic insulin resistance, which in normal individuals leads to, FFA
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potentiated, glucose stimulated, insulin release. In DM it is thought that FFA’s fail to 
stimulate insulin secretion. This leads to unchecked hepatic and peripheral insulin 
resistance which in turn lead to increased hepatic gluconeogenesis and decreased 
utilisation of glucose in the peripheral tissues [18]. Studies have also shown that there is 
reduced post-prandial FFA metabolism in abdominal obese, insulin resistant patients as 
compared to peripherally fat individuals so perpetuating the problem [19].
In obesity FFA’s may cause both peripheral insulin resistance and compensatory 
increase in insulin secretion [20]. The consequence of long term high FFA exposure 
appears to be more complex. Compared to glucose FFA’s are weak insulin secretagogues.
The cytokine tumour necrosis factor-(X (TNF-(X may also have a role in peripheral insulin 
resistance in obesity. TNF-(X levels are elevated in the adipose tissue of obese insulin 
resistant individuals [21]. The mechanism by which TNF-Oi may influence insulin 
resistance may be by the release of TNF-(X from adipose tissue. Levels of TNF-(X in the 
circulation are low and neutralisation of TNF-(X by antibody for 4 weeks has little effect 
on insulin resistance in obese patients with type 2 DM [22]. TNF-a may act locally on 
muscle [23] or may act indirectly via another factor. This factor may be FFA’s. This 
latter hypothesis is supported by observations that neutralisation of TNF-ot in Zucker rats 
is associated not only with an increase in insulin sensitivity but also a decrease in FFA 
levels [21] and that infusion of TNF-Oi in humans leads to an increase in plasma FFA 
levels [24].
There is a 4-hour lag period between the rise of plasma FFA’s and the onset of inhibition 
of insulin stimulated glucose uptake. This may prevent insulin resistance in non-obese 
individuals after a fat rich meal as FFA levels seldom remain elevated that long. In obese 
individuals FFA levels are persistently elevated and peripheral insulin resistance
19
mediated by FFA’s may occur. The elevated FFA levels will stimulate the release of 
insulin to compensate. The increase in FFA’s may in addition increase hepatic 
gluconeogenesis [25]. In obese patients genetically prone to developing DM the ability 
to release compensatory insulin may be lost eventually. Thus FFA increased insulin 
resistance and increase gluconeogenesis would go unchecked leading to hyperglycaemia. 
This in turn would produce progressively more islet ^-cell desensitisation and more 
peripheral resistance [18].
At the skeletal muscle level, high FFA’s compete with glucose for insulin stimulated 
glucose metabolism-the glucose-fatty acid cycle [26] leading to the inhibition of both 
glucose oxidation and storage. Strong negative associations have been found between 
waist; hip ratio and insulin stimulated glucose oxidation and also insulin stimulation of 
glycogen synthase activity. It has also been found that FFA’s inhibit the uptake of 
glucose in a dose dependant manner throughout the physiological range of plasma FFA 
concentration (-50 to -SOOpmol/l) [27]. The contribution of FFA’s to insulin resistance 
is at maximum only 50%. At levels of comparable euglycaemia and low plasma FFA 
concentration (<100 pmol/1) levels of insulin stimulated glucose uptake in-patients with 
diabetes ar e half of that seen in normal individuals [28]. It should also be noted that the 
increased insulin resistance induced by FFA’s has a physiological role to preserve 
glucose for metabolism in the CNS at times when glucose is scarce i.e. times of 
starvation, or prolonged exercise and also in late pregnancy. It is only in the obese state 
that they become pathological.
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1.1.2 Dyslipidaemia
The original concept written of the insulin resistance syndrome by Reaven in his seminal 
paper in 1988 was of an association of insulin resistance with hypertriglyceridaemia and 
with low HDL-cholesterol levels. The potential link with LDL-cholesterol concentration 
and composition was not considered [9]. It was not until 1991 that it was realised that an 
insulin resistant state does not lead to large changes in LDL-cholesterol levels but rather 
to increases in levels of LDL apolipoprotein (apo) B levels [29]. There is 1 apoB 
molecule for each LDL-cholesterol molecule so the presence of increasing apoB 
concentrations without concomitant rise in LDL-cholesterol levels suggests an increase in 
the number of cholesteryl ester depleted LDL molecules which are small and dense [30]. 
The production of apoB appears to be substrate-regulated [31]. Conversely it has been 
shown that high cholesterol levels, associated with large buoyant LDL-cholesterol 
particles are not indicative of a hyperinsulinaemic state [32].
Adipose tissue is the body’s largest energy store and as such has a central role to play in 
co-ordinating the use of energy. The storage and release of energy is lai'gely controlled 
by insulin via inhibition of lipolysis and enhancement of lipogenesis. Lipoprotein lipase 
(LPL) in adipose tissue hydrolyses triacyglycerol (triglyceride) in circulating 
triacylglycerol containing lipoproteins making FFA’s available for uptake into tissues and 
subsequent storage as triacyglycerol. This process is enhanced by insulin in the healthy 
state by enhancing transcription of LPL [33]. Insulin has the opposite effect in skeletal 
muscle promoting energy utilisation rather than storage [33].
The most common dyslipidaemia associated with DM is raised triglycerides due to an 
excess of very low-density lipoprotein (VLDL). This is caused by reduced clearance of 
VLDL by insulin sensitive enzyme LPL and in type 2 DM by increased VLDL
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production [34]. The presence of small dense LDL phenotype is also associated with 
hypertriglyceridaemia [35]. It is thought that this is due to an over production of apoB 
due in turn to an increased availability of FFA’s.
The smaller dense LDL-cholesterol molecules are less able to react with the LDL 
receptors, which increases the proportion of LDL-cholesterol, which can react with 
receptors for modified LDL on macrophages thereby increasing the formation of foam 
cells. In addition the metabolism of smaller dense LDL-cholesterol is slower resulting in 
longer residence of these particles in the circulation. Once again increasing its 
atherogenic potential [36] [37].
1.1.3 Prothrombotic Changes
Many abnormalities consistent with a procoagulant state are also associated with type2 
DM [38]. In type 2DM an increase in platelet agrégation, via decreased cAMP and 
cGMP production, is seen. The synthesis and activity of thromboxane, procoagulants, 
fibrinogen and von Willebrand’s factor are known to be increased. The concentration 
and activity of antithrombin factors including antithrombin III is in contrast decreased.
All of these lead to an increased predisposition to thrombosis [38]. This tendency to 
coagulation is further enhanced by a decrease in fibrinolysis due to a decrease in tPA 
activity and an increase in PAI-1 synthesis and activity (directly increased by insulin and 
IGF-1) [39]. This tendency is also increased by a decrease in the concentration of (Xl 
antiplasmin [39].
From the Framingham data fibrinogen levels were seen to rise across the range of blood 
sugar levels. A relationship between fibrinogen levels and cardiovasculai* events was
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established in the Gothenburg study, the North wick Park study as well as the 
Framingham study [40] [41] [42]. In the Framingham heart study in particular the risk of 
CHD was seen to be strongly associated with antecedent fibrinogen levels even after 
adjustment for diabetes and the standard risk factors. Antecedent fibrinogen levels were 
also related to risk of MI in men with a borderline significance in women. Wlien 
multivariate analysis was carried out and corrections applied for fibrinogen levels there 
remained a residual effect for glucose intolerance. Thus fibrinogen does not account for 
the residual effect of diabetes on incidence of CVD [43].
1.1/4 Endothelial Dysfunction
The endothelium provides not only a barrier and selective transport functions in vessel 
walls but also a surface facilitating assembly of prothrombinase derived through both 
tissue factors and the intrinsic pathway of the coagulation system. Endothelial cells can 
elaborate t-PA, PAI-1, prostacyclin, procoagulant factors e.g. von Willebrand factor, 
cytokines, adhesion molecules including selectins and giowth factors which can influence 
vascular smooth muscle migration and proliferation. Disturbance of endothelial 
dependent vasomotor function has been demonstrated in the coronary and forearm 
vessels of non-diabetic subjects both with established CHD [44] and those with risk 
factors for CHD [45] and may be important in the pathogenesis of atherothrombotic 
diseases.
There is considerable evidence in favour of endothelial dysfunction in type 2 DM, in 
particular in-patients with microalbuminuria [46]. Microalbuminuria may be thought of
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as the end result of increased vascular permeability secondary to endothelial dysfunction 
[47] [48]. It is also well established that CHD mortality increases with urinary albumin 
excretion rates in type 2 DM [49]. Microalbuminuria in type 2 DM is diminished by 
angiotensin converting enzyme (ACE) inhibitors known to potentiate bradykinin induced 
elaboration of t-PA by endothelium and to diminish elaboration of PAI-1 mediated 
metabolism of angiotensin [50] [51]. Serum ACE levels are associated with CHD risk 
and are found to be elevated in female patients with type 2 DM. This elevation has been 
traced to an insertion/deletion polymorphism in the ACE gene [52] which in turn has 
been linked to CHD mortality especially in patients with type 2 DM and few other risk 
factors [53].
Research has shown that the fibrinolytic paj’ameters PAI-1 and t-PA antigen, are strongly 
related to insulin resistance, HDL-cholesterol, triglyceride, body mass index, waist to hip 
ratio and blood pressure [54]. The concentration of PAI-1 is noted to be increased in type 
2 DM and in cardiovascular disease. Sobel et al found an increase in both total PAI-1 
(free plus plasminogen activator-complexed PAI-1) and a decrease in total urokinase 
plasminogen activator (free and receptor bound) in specimens of atheroma taken from 
patients with diabetes when compared to those without [39]. This suggests that in­
patients with a hyperinsulinaemic state as in type 2 DM there is an elevation of 
intramural PAI-1, which may contribute to an increase in thrombosis and accelerated 
vasculopathy. It has also been suggested that insulin may act either directly or indirectly 
via lipoprotein changes in the cells that synthesis PAI-1. Insulin is known to increase 
expression of PAI-1 in HepG2 cells (a human hepatoma line) and in concentrations 
consistent with type 2 DM insulin and proinsulin, its precursor, greatly increased 
elaboration of P A I1 from these cells [55].
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Juhan-Vague et al found that patients with angina pectoris exhibit elevated 
concentrations of PAI-1 in plasma [56]. Gray et al also demonstrated that patients with 
diabetes presenting [57] with acute MI had higher levels of PAI-1 and these could be 
correlated with level of glycosylation of haemoglobin and admission glucose. These 
findings are in accordance with those of Hamsten at al [58] [59] and Meade at al [41] 
who demonstrated high levels of t-PA inhibition in survivors of MI compared to control 
subjects. Impaired endogenous fibrinolytic activity may accelerate atherosclerosis by 
exposing vascular luminal wall surfaces to persistent and recurrent thrombi and clot- 
associated mitogens [39] [60].
Even modest caloric restriction can modify concentrations of insulin in elderly obese 
subjects, diminish elevated PAI-1 levels in blood and normalise several biochemical 
markers indicative of accelerated thrombosis [61]. PAI-1 expression in Hep G2 cells is 
also decreased by exposure to gemfibrizol [62]. This may explain the favourable impact 
of fibrates on mortality in the Helsinki Heart study affecting the fibrinolytic system rather 
than by an effect on lipids alone [63]. No association has been found between level of 
glycosylated haemoglobin and level of abnormal fibrinolysis. There is evidence to 
suggest that poor metabolic control may prevent clot lysis in that glycosylated fibrin is 
more resistant to plasmin digestion [64] and accumulation of fibrin is reported to occur in 
those tissues most affected by diabetic complications [65].
In addition other components of the insulin resistance syndrome may have a further 
detrimental effect on the endothelium. Increased plasma levels and oxidation of small, 
dense LDL-cholesterol leads to impaired endothelium-dependent vasodilatation by 
reducing prostacylin synthesis, increasing endothelin production and release and 
inactivation nitric oxide, [66] [67] while low HDL levels are associated with abnormal 
coronary artery vasoconstriction [68]. Oxidised LDL-cholesterol has also been shown to
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promote rapid adhesion of neutrophils to endothelium by up regulation of neutrophil 
adhesion receptors [69] and induction of cytokine release from human blood 
mononuclear cells [70].
1.2 Diabetes and Coronary Heart Disease.
1.2.1 Epidemiology
For patients with diabetes (type 1 or 2) the risk of cai'diovascular heart disease is greatly 
increased both for typel and type 2 [71]. In a survey in USA cardiovascular mortality 
was six fold greater in men and four fold greater in women than in subjects without DM, 
independent of other risk factors e.g. hypercholesterolaemia or hypertension [38]. The 
cardiovascular mortality for women with type 2 DM is four times that found in the 
general population [43]. The presence of type 2 DM also exacerbates the effect of other 
known cardiovascular risk factors. It leads to adverse changes in lipoprotein metabolism, 
body fat composition, blood pressure, fibrinolysis and the vasculature. The central 
mechanism behind these changes is insulin resistance.
There is a clearly recognised and researched sequence of events from impaired glucose 
tolerance to type 2 diabetes and then on to microvascular complications i.e. nephropathy, 
retinopathy and neuropathy. The same relationship does not appear to hold for 
macrovasculai' complications i.e. CHD, CVD, and PVD. In general, over 70 % of 
patients with DM die of macrovascular disease, mostly CHD. The increase in CHD is not 
related exclusively to glycaemic control [72]. Some studies suggest that patients with 
both established type 2 DM and those with impaired glucose tolerance (IGT) show the 
same relative risk of CHD. One possible reason for this is that macrovascular risk is
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associated with glycaemic levels lower than those employed currently to diagnose DM. 
This level is based on the risk of microvascular disease [73] [71].
The MRFIT study [74] examined the predictors of CVD mortality among men with and 
without diabetes and also the independent effect of diabetes (type 1 and 2) on 
cardiovascular mortality and morbidity. Approximately 350,000 men, aged 35-57, were 
followed up for an average of 12 years. The absolute risk of CVD death was much 
higher for diabetic than nondiabetic men of average age group, ethnic background and 
risk factor level. Overall the relative risk was 3.0 times higher when adjustments were 
made for age, race, income, serum cholesterol level, systolic blood pressure and reported 
smoking history (p<0.0001).
Diabetes is the only common condition, which increases the risk of heart disease in 
women to a level approaching that seen in men [75]. In the Rancho Bernardo Study and 
its subsequent follow up study, diabetes was found to be an independent predictor for 
heart disease in both men and women but most strongly in the women. The relative 
hazard of ischaemic heart disease deaths in diabetics being 1.8 in men and 3.3 in women 
after adjusting for age and 1.9 and 3.3 respectively after adjusting for age, blood pressure, 
cholesterol levels, body mass index and smoking using a Cox regression model [76]. 
Conventional risk factors do not account for this excess, and attention has focused on the 
possible contribution of abnormalities of fibrinolysis and coagulation in type 2DM.
1.2.2 Lipids
Early primary and secondary cardiovascular prevention trials of lipid lowering therapy 
have included diabetic patients, although in very small numbers. (Table 1.1, 1.2-statin
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trials) Subgroup analysis of the WOSCOPS trial [77], a large primary cardiovascular 
prevention trial of 6595 patients, 66 of whom had type 2 DM, using pravastatin, revealed 
that the reduction in cholesterol and in morbidity and mortality from CHD from the use 
of pravastatin was the same in those with or without DM. Pravastatin reduces the 
incidence of fatal and nonfatal coronary events in middle-aged men with moderately 
elevated cholesterol (LDL-chol >4mmol/l) and no history of myocardial infarction by 
31%. (95% Cl 17-43 p<0.001) The need for coronary angiogiaphy and revascularisation 
procedures was also lowered by approximately 31(95% Cl 10-47 p=0.007) and 37 % 
(95% CIl 1-56 P=0.009) respectively. The number of patients with diabetes was too 
small for subgroup analysis to be meaningful (approximately 1 % of patients). The same 
is true of the AFCAPS/TEXCAPS study using lovastatin for primary prevention.
In the Helsinki Heart trial [78] [79] a primary prevention trial of 4081 patients using the 
fibrate gemfibrozil, 135 participants had DM. In this group there were 8 events due to 
CHD in the placebo group (n=76) and only 2 in the treatment group (n=59). The 
reduction in risk in these 2 gioups was not significant (Table 1.3-fibrate trials). Subgroup 
analysis of the VA-HIT trial [80], which also utilised gemfibrizol in 2531 patients, 633 of 
whom had DM, but for secondary prevention of CHD revealed a significant reduction in 
the primary combined endpoint of death and nonfatal MI and stroke of the order of 24% 
which was consistent with that seen in patients without type2 DM. Analysis of trial 
evidence shows that in patients with DM and dyslipidaemia the development of 
proteinuria is a particularly strong predictor of CHD risk and as such these patients 
should then be treated as in secondary CHD prevention [81].
Subgroup analyses from the three large secondary prevention statin studies i.e. 4S [86] 
[83], CARE [84] and LIPID [85] studies have been published (Table 1.1, 1.2-statin 
trials). In the 48 study 202 patients with DM were recruited (-4%  of study population).
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There was a 43% decrease in all cause mortality (p nonsignificant) and a 55% decrease in 
CHD incidence (p=0.002) in those treated with simvastatin. This result is equivalent to 
that seen in patients without diabetes. The patients in the 4S study were unrepresentative 
of the diabetic population as a whole as individuals with triglyceride levels above 
2.5mmol/1 were excluded. Thus many patients with typical DM dysliproteinaemia were 
excluded.
In the CARE study 586 patients with diabetes (-15%  of the study population) were 
recruited. Treatment with pravastatin in this gioup lowered the CHD incidence by 25% 
(95% Cl 0-43, p=0.05) a level comparable with that seen in patients without diabetes.
The exclusion criteria for this study were plasma cholesterol >6.2mmol/l, LDL-Chol >
4.5mmol/1 and triglyceride > 4.0mmol/l. The subgroup included patients with previously 
diagnosed DM, those with DM diagnosed during the study by a glucose tolerance test and 
also those with impaired glucose tolerance. It is not clear whether patients were stratified 
in the study during randomisation as to the presence or absence of DM.
In the LIPID study only 164 patients with diabetes were recruited (-2%  of the study 
group). A fall of 19% in deaths due to CHD was found in this group with pravastatin 
treatment but this was not significantly different from patients with DM in the placebo 
group
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Table 1.1 
Statin Trials.
Trial WOSCOPS
[77]
AFCAPS/TEXCAPS
[82]
4S
[83]
CARE
[84]
LIPID
[85]
Drug pravastatin lovastatin simvastatin pravastatin pravastatin
Total
recruited
6595 6605 4444 4159 9014
No. DM 66 (1%) 60 (0.9%) 202 (4.5%) 586
(14.1%)
164(1.8%)
No.
Women
0 600 (9.1%) 800(18%) 582
(13.9%)
1532
(17%)
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Table 1.2
Statin Trials. (Figures are significant unless otherwise stated.)
End Point (% redn) Total Popn DM Women
WOSCOPS 
Total Mortality 22 22 0
CFID Incidence 31 31 0
AFCAPS/TEXCAPS 
Total Mortality ns ns ns
CHD Incidence 37 37 46
4S
Total Mortality 30 ns ns
CHD Incidence 33 55 ns
CHD Mortality 42 ns ns
CAB G/Angi oplasty 37 32 49
CARE
Total Mortality ns ns ns
CHD Incidence 23 25 51
CHD Mortality 24 3 ns
CABG/Angioplasty 27 32 45
LIPID
Total Mortality 22 ns ns
CHD Incidence 24 ns ns
CHD Mortality & nonfatal MI 25 19 ns
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Table 1.3
Fibrate Trials (Figures are significant unless otherwise stated.)
End point (%Reduction) Total Popn DM
Helsinki Heart Trial
(gemfibrizol)[79] [78]
Total Mortality ns ns
CHD Incidence 34 ns
CHD Deaths 26 ns
VA-HlT
(gemfibrizol) [80]
Total Mortality ns ns
CHD Deaths 22 ns
CHD Incidence 23 ns
Combined end point(death, nonfatal MI & CVA) 24 24
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It has become clinical practice to give lipid lowering statin therapy to patients with 
diabetes whose cholesterol is raised over 5mmol/1 when triglycerides are less than 
5mmol/1 despite diet therapy. Hypertriglyceridaemia is more common in patients with 
diabetes and the most appropriate lipid lowering drug is less certain when 
hypertriglyceridaemia is pronounced or when triglycerides are raised but cholesterol is 
relatively low [87]. Wliether such patients would benefit more from fibrates alone or a 
combination of fibrate and statin is at present the subject of clinical trials.
1.2.3 Hypertension
Implicit within the insulin resistance syndrome it is seen that hypertension is very 
common in patients with type 2DM. 40% of patients at diagnosis of DM have 
hypertension [88]. Insulin resistance is linked to hypertension [9]. The exact mechanism 
of association remains to be resolved. Possibilities include insulin-mediated renal sodium 
reabsorption in the proximal tubule, increased sympathetic activity and catecholamine 
secretion and increased activity of the renin-angiotensin system [9].
The Hypertension in Diabetes (HDS) study revealed hypertension is strongly related to 
obesity and is highly predictive of cardiovascular complications [88]. In type 2 DM, 
hypertension does not usually indicate the presence or development of nephropathy. If 
present, hypertension will accelerate the decline of renal function in patients with 
established nephropathy [89]. The United Kingdom Prospective Diabetes Study 
(UKPDS), which is the follow on clinical study of the HDS have provided important new 
evidence on treating hypertension in patients with type2 DM (Table 1.4, 1.5 - 
hypertension trials)
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In the UKPDS study J 148 hypertensive patients (mean age 56, mean BP at entry 
160/94mmHg) were recruited [90] [91]. Patients were then randomly allocated to receive 
tight control of blood pressure (n=758) or less tight control (n=390). Follow up was for a 
median time of 8.4 years. Mean blood pressure during follow up was significantly 
reduced in the group assigned tight control (144/82mmHg) compared to the group 
assigned to less tight control (154/87mmHg) (p<0.0001). Reductions in risk in the group 
assigned to tight control compared to less tight control were 24% in diabetes related end 
points (95% Cl 8-38%, p=0.0046), 32% in deaths related to diabetes (95% Cl 6-51%, 
p0.019), 44% in strokes (95% Cl 11-65%, p=0.013) 21% in MI (p=0.13) and 37% in 
microvascular end points (95%CI 11-56%, p=0.0092). There was non-significant 
reduction in all cause mortality. (p=0.17). After 9 years of follow up, 29% of patients in 
the group assigned to tight control required 3 or more treatments to lower BP to the 
desired level. Captopril and atenolol were equally effective in reducing blood pressure to 
a mean of 144/83mmHg and 143/8 ImmHg respectively and reducing the risk of 
macrovascular end points. A similar proportion of patients required 3 or more 
antihypertensive agents at the end of follow up in the 2 groups. Analysis in this trial was 
done on intention to treat basis.
All patients with type 2 DM should be treated to attain a blood pressure of <80mmHg 
diastolic whether it is with an atenolol or ACE inhibitor based regimen. Subgroup 
analysis of other outcome trials also supports the use of other antihypertensive 
medication. Thiazide diuretics, which were previously contraindicated in DM, 
substantially improve the prognosis of patients with hypertension and type 2 DM [94]. In 
the Syst-Eur trial treatment based on nitrendipine, a dihydropyridine calcium antagonist, 
also had clear benefit in patients with isolated hypertension and DM [97] (table 1.4, 1.5- 
hypertension trials).
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Table 1.4
Hypertension Trials
Trial UKPDS [90] 
[91]
HOT [92] [93] SHE? [94] SYST-EURO 
[95] [96]
Drug Captopril,
atenolol
felodipine chlorthalidone nitrendipine
Total recruited 1148 18790 4763 4695
No. DM 1148 1501 (8%) 583 (12%) 492 (10%)
No. Women 920 (80%) 8831 (47%) 2715 (57%) 3138 (67%)
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Table 1.5
Hypertension Trials (Figures are significant unless otherwise stated.)
End Point (% redn) Total Popn DM
UKPDS 
Total Mortality ns ns
CHD Incidence 21 21
CVA Incidence 44 44
Microvascular Incidence 37 37
HOT
Total Mortality 9 9
CHD Deaths 15 29
CHD Incidence 53 51
CVA Incidence 45 48
SHEP
Total Mortality 15 26
CFID Incidence 29 56
CVA Incidence 38 22
SYST-EURO 
Total Mortality ns 55
CHD Deaths ns 76
CHD Incidence 26 69
CVA Incidence 38 73
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1.3 Women and Cardiovascular Disease.
1.3 Epidemiology
Cardiovascular disease (CVD) particularly coronary heart disease is the leading cause of 
death among women aged 60 years and older [98] [99] [100]. Cardiovascular disease 
deaths, primarily from CHD outnumber the next 16 causes of death in women combined, 
including all cancers [101]. Women are 4 to 8 times more likely to die of CVD than of 
any other disease. Since 1980 death from CVD has declined dramatically in men, 
whereas it has increased in women. Since 1984 annual CVD mortality in women in USA 
has exceeded that of men by about 50,000 a year.
It is a well-recognised fact that women live longer than men. This difference is apparent 
from birth and continues to rise with age especially as fewer women now die in 
childbirth. In most industrialised countries the largest reason for this sex differential is 
coronary heart disease. The sex ratio remains almost constant across countries with 
varying diets, cultural habits and heart disease rates at 2.5-4.5 [102]. This holds even 
though women in general are more obese have higher blood pressure, higher plasma 
cholesterol, higher fibrinogen levels and more diabetes than men. There is a gender- 
mediated difference that could be explained most simply by the hypothesis that oestrogen 
is protective.
Despite evidence to the contrary a common perception exists that CVD affects mainly 
men and is not a serious problem for women. This perception has arisen pai'tly from the 
sex difference at age of first presentation of symptoms. In general, in subjects without 
DM, CHD begins a decade later in women than men. Women develop angina 10 years 
later and have their first myocardial infarction (MI) 20 years later than men [98] [103].
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An additional reason for the misconception is that chest pain is less likely to be 
associated with substantial coronary artery disease in women. This has resulted in sex 
differences in outcomes after diagnosis of angina. In the Framingham study although 
more women (47%) than men (29%) had angina as a presenting symptom it led to more 
serious disease in only 19% of women compared to 44% of men [104]. Similarly men 
were found to have 43% of Mi's compared to 29% in women. In the Myocardial 
Infarction and Intervention Registry (MITI) study [105] and a further multicentre study 
which examined the numbers of patients presenting with acute chest pain that went onto 
develop MI, [106] more men had M i’s than women.
A possible explanation for this is that chest pain syndromes in women are more likely to 
be accompanied by normal coronary arteries at angiography. In the Coronary Artery 
Surgery Study (CASS) 50% of women and 17% of men with ehest pain had minimal or 
no coronary arterial narrowing [107]. Women with chest pain may either not have CHD 
or if present the prognosis for their CHD is benign. A consequence of this has been that 
the participation of women in both primary and secondary prevention trials has been 
minimal until recently.
In addition, exercise treadmill testing is less specific in women than in men thus it has not 
been utilised as a diagnostic tool as widely in women as in men [108] [109] [110]. The 
specificity and sensitivity can be greatly increased by the addition of thallium to the 
treadmill test [111]. Women are also less likely to undergo coronary angiography or 
percutaneous transluminal coronary angioplasty (PTCA). Among patients with ejection 
fraction of less than 0.40 after MI enrolled in the Survival and Ventricular Enlargement 
(SAVE) study, men were twice as likely to have undergone a cardiac procedure prior to 
the index infarction even though women reported greater functional disability from
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angina before the MI [112]. Once a diagnosis of CHD is made in women referral rates 
for PTCA and coronary artery bypass grafting (CABG) are equivalent [113].
Despite these difficulties, early diagnosis of CHD in women is important as two thirds of 
sudden deaths occur in women with no CHD history [98]. Women also have a poorer 
prognosis and more severe outcome after MI, PTCA and CABG compared to men [98]. 
Women are more likely to die from a first MI than men and for those who survive there is 
a higher risk of re-infarction and death [98]. In the Framingham Heart Study, 44% of 
women who had an MI died within 1 year, compared to 27% of men [99]. Some of the 
sex differences in prognosis from CHD between the sexes can be attributed to the greater 
age of women at which they develop the disease, as outlined before. Age is a non- 
modifiable risk factor for CHD hence the importance of early diagnosis is once again 
reinforced.
1.3.2 Lipids
Natural menopause confers a 3-fold increase in CHD risk [99]. In the Nurses’ Health 
Study bilateral oophorectomy lead to an 8 fold increase in CHD risk [114]. After the age 
of 50 cholesterol levels remain static in men. Levels of low density lipoprotein (LDL) 
cholesterol increase on average by 0.05mmol/l per year in women from age 40 to 60 in 
women [115]. At least part of this increase is due to declining oestrogen levels leading to 
down-regulation of LDL-receptors in the liver [116] [117]. A high LDL-cholesterol level 
is a strong predictor of CHD risk in women under 65 but its predictive power lessens 
after this age [118]. At menopause levels of total cholesterol, very low density (VLDL) 
cholesterol and triglycerides (TG) have also been observed to increase as do small dense 
LDL cholesterol particles [116] [117]. The increase in the latter, being associated with a 
3-fold increase in MI risk [119].
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In the National Health and Nutrition Examination Surveys (NHANES), a cross sectional 
study, high-density lipoprotein (HDL) cholesterol levels were observed to be lower in 
men than in women and did not appear to change with age [115]. In 2 further 
longitudinal studies levels of HDL-cholesterol decreased in postmenopausal women 
[117] [120]. It is now appreciated that low HDL-cholesterol is a stronger predictor of 
CHD mortality in women than in men especially in women 65 and over [121] [118]
[122]. The HDL2 cholesterol subfraction is especially prone to fall after the menopause. 
This subfraction is thought to be more cardioprotective than either the HDL-1 or HDL-3 
sub-fractions [117]. In a study of women over 70 years of age those with a HDL 
cholesterol of less than 0.9mmol/l had a relative risk of CHD mortality twice that of 
women with HDL cholesterol levels of 1.6mmol/l and above [122] [123].
The ratio of total cholesterol to HDL cholesterol is also important in CHD risk 
assessment. In the Framingham Heart Study, the 8 year risk of heart disease was 7% for 
women with a ratio less than 5, 12% for those with a ratio of 5 to 7 and 20% for those 
with a ratio over 7 [99].
Increased TG levels may also be important in CHD risk and mortality in women. An 
analysis of population based prospective studies found a statistically significant increase 
in the risk of incident CVD of 14% in men and 37% in women after adjustment for HDL 
cholesterol level and other risk factors [124]. A prospective study of 1405 
postmenopausal women carried out for an average of 14 years reported a strong 
coiTelation between TG levels and death due to CVD [125]. TG levels over 4.50mmol/1 
were associated with a greater than 3 fold increase in risk of CVD mortality. Increases in 
TG levels are important in postmenopausal women especially when HDL cholesterol
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falls below 1.03mmol/1 [126] [127]. Average or high HDL cholesterol levels appear to 
attenuate the increase in CHD risk due to elevation of TG levels.
As mentioned earlier, female participation in both primary and secondary cardiovascular 
prevention trials has been limited. (See tables). Most studies have included men only or a 
small number of women. Only 2 primary prevention lipid lowering trials have included a 
large enough number of women without CHD to make analysis meaningful. The first 
study randomised patients including 1184 women to receive colestipol or placebo.
Follow up of these patients was for on average 2 years and a fall of 10% was observed in 
total cholesterol over this time. Unfortunately no effect was found on CHD mortality. 
(RR 0.93, 95% Cl 0.38-2.26) It can be seen from the wide confidence intervals that this 
study may not have been powered to show any effect on CHD mortality [128].
The main primary prevention trial including women was the Air Force/ Texas Coronary 
Atherosclerosis Study (AFCAFS/TexCAPS) (table 1.1-statin trials). Approximately 600 
women with average total and LDL cholesterol levels and below average HDL 
cholesterol levels (mean 1.03mmol/1) were recruited. At the end of the first year of 
treatment with lovastatin LDL cholesterol had been reduced by 25%, total cholesterol by 
18% and triglycerides by 15%. Over the same time period HDL cholesterol levels rose 
by 6%. All compared to placebo. After an average follow up time period of 5.2 years the 
risk of acute major coronary events (fatal and nonfatal MI, unstable angina and sudden 
cardiac death) was reduced by 37% in the treatment group compared to the placebo group 
(p<0.001). The reduction in risk was greater in the women recruited compared to the 
men (46% cf. 37%). This difference was not significant due to the small number of 
events in the female subgroup (7 in the lovastatin group vs. 13 in the placebo group). The 
trial unfortunately had insufficient power to examine CHD mortality or total mortality 
[82].
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Women were slightly better represented in the major secondary prevention trials. (Table 
1.1) In the 4S study 800 women were included in the recruitment to be randomised to 
receive simvastatin [129]. At the mid point of the trial active treatment had reduced LDL 
cholesterol levels by 37.4% in women and significantly reduced the risk of the combined 
end point (all cause mortality, CHD death, non fatal MI or resuscitated cardiac ai rest) by 
34% in both men and women. The need for PTCA or CABG was reduced by 49% in 
women (95%CI 0.30-0.86). Total mortality was not reduced in women (RR 1.16, 95%
Cl 0.68-1.99). There was also no reduction in CHD mortality in the females. These 
findings reflect a lower total mortality and CLID mortality in the women in the placebo 
group than the men (6% and 4% cf. 13% and 8% respectively). The authors of the study 
thought the lower mortality figures in the females could have been due to women being 
recruited more on the basis of a history of angina alone than their male counterparts and 
since in women this is not always an indicator of abnormal coronary arteries as 
previously discussed, this may have affected the outcome data. The importance of 
considering the sex differences in CHD in men and women when examining trial results 
which recruit on the basis of angina alone rather than CHD confirmed by angiography or 
on basis of a confirmed MI is important.
In the Cholesterol and Recurrent Events (CARE) trial [130] 582 women with a confirmed 
history of MI and mean LDL cholesterol of 3.59mmol/l were randomized to receive 
pravastatin or placebo. After 5 years of follow up the women in the active treatment 
group had a 43% reduction in CHD death or nonfatal MI. This is compared to the men in 
the same group who showed a reduction of only 21%. Although CHD mortality was 
significantly reduced in men but not in women, women had a greater reduction in 
nonfatal MI (51%) compared with men (15%). The need for PTCA or CABG was
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decreased by 48% and 39%, respectively, in women compared with 17% and 24% in 
men. Women experienced a 56% reduction in stroke (p=0.07).
In the LIPID trial [85] 1532 of the 9014 recruits were women with confirmed angina or 
MI After 6.2 years of follow up a non-significant 11% reduction in CHD death or 
nonfatal MI was reported in the women (cf. a significant 26% reduction in men). 
Significant outcome data was reported for the whole group but not for the female cohort 
alone.
A sub-study of the Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) 
examined the effect of lovavastatin over 2 years of treatment on coronary angiograms in 
women with diffuse coronary atherosclerosis, various coronary risk factors and total 
cholesterol between 5.69 and 7.76mmol/l. Lovastatin lowered LDL cholesterol by 32% 
and total cholesterol by 24% compared to the levels in the placebo group. It also 
decreased the progression of atherosclerosis seen on repeated angiograms [131].
It can therefore be seen that primary and secondary trials of statins have shown 
substantial benefits in women. Up to 46% reduction in major coronary events has been 
demonstrated as well as significant benefits in lipoprotein levels.
1.3.3 Hypertension
Elevated systolic and diastolic blood pressure confers an increased risk of CHD in both 
men and women. Women with hypertension have a 4-fold risk of heart disease compared 
to normotensive women. This compares to a 3-fold increase in men with hypertension 
[121] [132]. Isolated systolic hypertension in older women, is of particular concern in 
terms of CHD risk [121]. The prevalence of hypertension increases with age and because
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of their survival advantage women with hypertension out-number men with hypertension 
in the older age gi'oups. There is an estimated prevalence of hypertension of 60% in 
women over 45 years of age, (identified as a blood pressure >140/90mmHg or use of 
antihypertensive medication) [121].
Women have been well represented in the hypertension trials. (Table 1.3) No subgroup 
analysis has been published in these.
1.4 Current treatment of postmenopausal women with type 2 DM
1.4.1 Primary Prevention
1.4.1.1 Estimating Risk
In the past investigators with the Framingham Heart Study developed CHD risk equations 
for use by clinicians in predicting the development of coronary disease in individuals free 
from disease [133]. These equations reflected the study investigators experience of 
follow up from 1950 to the mid 1960’s [134]. A handbook of these equations was 
published in 1973 [135]. Further modifications have been made since then taking 
account of HDL cholesterol levels measured in the Framingham cohort from 1968 and 
also older age group experience. Data has also now been incorporated from the 
Framingham Offspring Cohort study. Estimates of CHD risk have now been produced 
that reflect the approximate combination impacts of total and HDL cholesterol, systolic 
or diastolic blood pressure, cigarette smoking, diabetes and left ventricular hypertrophy 
as measured by echocardiography. Risk prediction charts have been drawn up jointly by 
the British Cardiac Society, the British Hypertension Society, the British
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Hyperlipidaemia Association and the British Diabetic Association and management can 
be adjusted accordingly. From these charts risk is estimated as less than 15%, 15-30% or 
greater than 30% over the next 10 years.
Blood pressure and serum cholesterol levels exhibit a log linear relation with risk of CHD 
in prospective epidemiological studies. There seems to be little evidence of a lower 
threshold. For a given proportional reduction in risk factor a proportional reduction in 
CHD risk will be seen. The absolute risk reduction i.e. the benefit to the patient will 
depend on the patient’s baseline absolute risk. Evidence from clinical trials has 
unequivocally shown that individuals with an absolute CHD risk as low as 15% 
(equivalent to a cardiovascular risk of 20%) over 10 years do benefit from blood pressure 
and lipid lowering interventions that lower coronary and cardiovascular morbidity and 
mortality. The cost and logistical implications for such an intervention are prohibitive. 
Professional bodies have recommended that, at a minimum, individuals with and absolute 
CHD risk of 30% over 10 years be tai'geted for comprehensive risk factor management. 
This should include as appropriate blood pressure and lipid lowering therapy. There is 
evidence from both local and national audits e.g. the ASPIRE study that the risk factors 
in this group of patients has not as yet been fully addressed [136]. The exceptions to 
treatment in the context of absolute CHD risk are patients with malignant hypertension, 
familial hypercholesterolaemia or other inherited dyslipidaemia or patients with diabetes 
with associated target organ damage.
1.4.1.2 Treatment of Diabetes
Treatment includes aggressive management of glycaemia. Each 1% reduction in HbAlc 
is associated with a 21% reduction in diabetes related death and in particular a 14% 
reduction in MI over lOyears. No lower threshold has been found for this effect [137].
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Intensive treatment with insulin in patients with type 1 DM can lead to a 40% reduction 
in cai’diovascular events [138]. In the UKPDS a significant decrease in risk of 
microvascular but not macrovascular disease in patients with type2 DM was seen when 
glycaemia was treated regardless of treatment regimen i.e. insulin or sulphonylurea [139]. 
The reduction in incidence of MI did reach borderline significance (p=0.052) which the 
researchers felt indicated that the beneficial effect of intensive glucose control 
outweighed the theoretical risk of the anti diabetic agent. This would suggest that 
metabolic control of diabetes is important in prevention of CVD. Intensified insulin 
regimens are known to be associated with a less atherogenic profile of lipoproteins than 
intensive therapy with oral hypoglycaemic agents [140] [141].
1.4.1.3 Treatment of Hypertension
Collins and MacMahon examined in a meta-analysis 17 trials involving almost 50,000 
patients with a mean follow up of 4.9 years. A fall in diastolic blood pressure on 
treatment of 5-6mmHg was achieved. This was associated with a significant reduction in 
fatal and nonfatal stroke (38%) and fatal and nonfatal MI (16%). No significant 
differences were found between the trials examined [142]. All cause mortality was also 
seen to fall by 12% due to nonvascular deaths being evenly distributed between the 
treatment groups. A 20-25% reduction in CHD events was expected rather than 16% 
observed. It may be that most of the randomised, controlled trials of blood pressure 
treatment on CHD risk provide an underestimate of the reduction due to several factors. 
These included the fact that the trials were usually short term, relatively low risk patients 
were recruited to the trials preferentially, those with concomitant disease or end organ 
damage were excluded generally and up to 25% of patients assigned to the placebo arm
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of trials (those with the highest blood pressure) were switched to active therapy. These 
factors converge to reduce the absolute risk reduction detected [143].
Hypertension can be addressed by lifestyle modification and drug therapy to achieve a 
diastolic BP <80mmHg and systolic BP <140mmHg [92]. Cardiovascular risk increases 
across the whole range of blood pressure. Intervention is recommended from a level at 
which trial evidence has shown intervention reduces cardiovascular risk. Evidence from 
both observational and randomised trials show that cardiovascular risk is equally strongly 
linked to either systolic or diastolic blood pressure [5].
1.4.1.4 Lipid Lowering Therapy
Meta-analyses of primary prevention trials have in general shown that reduction of 
cholesterol leads to a lowering of CHD risk [144] [145] [146] [147] [148] [149]. This is 
true whether the method of reduction is diet or diet and drugs. It is estimated that for a 
10% fall in cholesterol there is a 25% fall in CHD risk [144]. This is equivalent to an 
average 0.6mmol/l fall in most trials. This fall in CHD risk is achieved after only 2 years 
on treatment.
It is reconunended in the SIGN 40 guidelines that lipid lowering therapy is commenced 
if lOyear CVD risk is >30% when serum total cholesterol is >5mmol/l [150]. Women 
should be considered for lipid lowering at the same threshold as men.
Triglycerides are an independent risk factor of cardiovascular disease in type 2 DM 
[151]. Trials are currently underway to assess the reduction in CVD risk by lowering TG 
levels.
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1.4.] .5 Antiplatelet Therapy
The use of aspirin and other antiplatelet drugs had not been recommended for primary 
prevention of CHD until the results of the Hypertension Optimal Treatment (HOT) trial 
were published. In this trial low dose (75mg) aspirin was used in conjunction with 
medication to control blood pressure in patients with atherosclerotic complications or 
who had target organ damage due to hypertension e.g. left ventricular hypertrophy, 
proteinuria or renal impairment. The group who received aspirin was seen to benefit 
more than those who did not [92]. Additional evidence as to the validity of prescribing 
aspirin for primary prevention has been provided by the MRC thrombosis prevention trial 
of aspirin and warfarin in which men at high risk of CHD, regardless of presence of 
hypertension, benefited from aspirin therapy [152]. Antiplatelet therapy, in the form of 
aspirin in the first instance, is commenced if CVD risk is >20% over lOyears [153].
1.4.2 Secondary Prevention
Most of the evidence for prevention in this area comes from trials undertaken after Ml. 
Patients with angina and those following cardiovascular intervention especially 
percutaneous transluminal coronary angioplasty have not been extensively studied, but 
where evidence does exist e.g. aspirin in angina or lipid lowering following coronary 
artery bypass grafting the results are generally consistent with those found post-Ml [154] 
[85].
For married couples there is a concordance for lifestyle and risk factors such as obesity, 
hypertension lipids and glucose [155]. There is no trial evidence in favour of stopping
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smoking following the development of CHD, but observational data shows that the risk 
of recurrent disease is reduced by -50%  within 1 year of stopping and a favourable effect 
on mortality is sustained for more than 10 years [156]. In the action on secondary 
prevention through intervention to reduce events (ASPIRE) study 1 in 5 patients had 
resumed smoking at follow up [136]. Uncertainty exists about the use of nicotine 
replacement therapy in patients with CHD, or other atherosclerotic disease as some of the 
cardiotoxic effects of smoking are attributable to nicotine. A short-term trial of 
transdermal nicotine in patients with CHD has shown no significant rise in cardiovascular 
risk [157].
1.4.2.1 Treatment of Hypertension
Raised blood pressure continues to be a risk factor for subsequent cardiovascular events 
after an MI [158]. Twenty five percent of patients with hypertension also have a history 
of angina, MI or both [159]. Despite this no clinical trials of antihypertensive treatment 
in patients with established CHD have been carried out. Results from primary prevention 
trials are therefore extrapolated to secondary prevention in treatment of hypertension.
The use of p blockers during and after MI leads to a 23% reduction in mortality in 
survivors [160]. The use of rate limiting calcium antagonists (verapamil and diltiazem) 
in MI survivors leads to a reduction in all cause mortality as well as deaths from recurrent 
MI. The benefits are restricted to patients without left ventricular impairment [161]. p 
blockers are the preferred treatment option post-MI and verapamil or diltiazem are 
recommended if P blockers are contraindicated or not tolerated.
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Angiotensin converting enzyme (ACE) inhibitors aie indicated for patients following MI, 
primarily for those with evidence of heart failure in the acute phase and for those in 
whom there is left ventricular dysfunction i.e. ejection fraction less then 40% [162] [163].
The relationship between death and blood pressure is J-shaped and concern has been 
raised that lowering of the diastolic blood pressure may lead to increasing rates of death 
due to CHD especially in those hypertensive patients with co-existing CHD or left 
ventricular hypertrophy [164] [165]. These concerns were based on the knowledge that 
maximum cardiac blood flow occurs during diastole. The theory has not been supported 
by trials of treatment of hypertension in the elderly [94], a proportion of whom were 
likely to have at least preclinical CHD or in trials of the treatment of heart failure in 
which low levels of blood pressure were attained [162].
1.4.2.2 Lipid Lowering Therapy
Serum cholesterol and HDL-cholesterol continue to be risk factors for recurrent CHD 
events after MI [166]. A meta-analysis was conducted, before the major statin trials 
reported. This included 21 trials employing diet, drugs (clofibrate, gemfibrizol, 
cholestyramine, colestipol, niacin) or partial ileal bypass surgery. The mean total 
cholesterol was 6mmol/l and the average reduction achieved was 10%. With this 
reduction a 10% reduction in mortality was achieved (95% Confidence Interval 3-16% 
p=0.008). There was no effect on non-cardiac mortality [145]. Prior to the statin trails 
angiographic evidence was also sought for confirmation of effects of lipid lowering. 
These revealed a significant lowering of the rate of angiographic progression and higher 
rates of angiographic regression of atheroma regardless of treatment moiety employed 
[167].
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The strongest evidence that lowering of cholesterol is beneficial in patients with existing 
CHD comes from the 3 main statin trials discussed earlier i.e. the 4S trial, the CARE trial 
and the LIPID trial. There is strong evidence that following an MI or identification of 
unstable angina statin therapy should be prescribed for patients with a total cholesterol of 
5mmol/1 or greater. The benefits for secondary prevention of CHD in patients with 
cholesterol levels under 5mmol/1 have not been established as yet. Similarly the benefit 
to patients with cerebrovascular disease or peripheral vascular disease is the subject of 
ongoing trials. In the ASPIRE study 78% of men and 86% of women had a cholesterol 
concentration of greater than 5mmol/l. Only a minority of patients were on statin therapy 
and of these 50% had not had sufficient dose to reduce their cholesterol level below 
5mmol/i. Another approach based on trial evidence is to reduce LDL cholesterol by 33% 
in secondary prevention. This will usually be aehieved if the statin doses used in the 
trials are prescribed [168].
1.4.2.3 Antiplatelet therapy
There is no single trial of aspirin used in patients with CHD which give definitive results. 
A meta-analysis of antiplatelet drug trials shows a 31% reduction in nonfatal re­
infarctions, a 42% reduction in nonfatal strokes and a 13% reduction in cardiovascular 
mortality. Aspirin in the dose range 75-325mg alone is as effective as aspirin in 
combination with either dipyridamole or sulphinpyrazone or at higher dose. It is 
recommended all patients with established CHD should be prescribed aspirin [154].
Oral anticoagulation with the coumarins e.g. warfarin, in MI survivors lowers the risk of 
reinfarction, coronary death, and stroke. Due to the considerable side effects these drugs
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are usually reserved for those patients with large anterior MI, left ventricular aneurysm, 
paroxysmal tachycardias, chronic heart failure and systemic embolic disease [169].
1.5 Summary
Type 2 DM is caused by an increase in insulin resistance (IR). The cause of this increase 
is complex and includes presence of increasing FFA’s. Type 2 DM is associated with 
dyslipidaemia (hypertriglyceridaemia and low HDL-c) endothelial dysfunction, a 
prothi'ombotic state and hypertension in Reaven’s Syndrome. It is also a recognized 
independent risk factor for cardiovascular disease.
Cardiovascular disease is the leading cause of death in women over 60. Despite this it 
often remains undiagnosed or misdiagnosed due to misconceptions and difficulties with 
testing. Women also have a much poorer prognosis from CVD than men. Menopause 
leads to a 3-fold increase in cardiovascular risk. The fall in oestrogen levels lead to 
deleterious effects on lipids and endothelium. Women have largely been excluded from 
the major primary and secondary cardiovascular prevention trials but do seem to benefit 
from lowering of LDL-c, blood pressure as well as antiplatelet therapy and better diabetic 
control.
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CHAPTER 2
HORMONE REPLACEMENT THERAPY (HRT)
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In 1936, Mocquot and Moricard described the first clinical use of androgens for the 
treatment of menopausal symptoms in women. In 1943, Salmon and Geist reported the 
effects of use of oestrogen therapy combined with either testosterone or 
methyl testosterone in postmenopausal women. Since then many postmenopausal women 
have been treated with ovarian hormones in an attempt to alleviate the symptoms of 
menopause and more recently in the hope of preventing osteoporosis and reducing the 
risk of ischaemic heart disease. The postmenopausal period has been simplistically 
considered an endocrine deficiency state and replacement therapy has been seen as 
restoring the premenopausal endocrine state. None of the available HRT regimens 
entirely mimic the pattern of hormone secretion prior to menopause. The most frequently 
used and most studied replacement regimen has been oestrogen alone. The relatively 
recent addition of progestogen does make the preparations more like those seen 
physiologically but they may negate some of the clinical benefits of oestrogen alone.
2.1 Types of HRT.
2.1.1 Oral Oestrogen
This is the mainstay of HRT therapy. Oral administration of oestrogen leads to hormone 
concentrations in hepatic sinusoidal blood that are 4 to 5 times higher than those in 
peripheral blood [170]. This first pass effect promotes the hepatic synthesis and secretion 
of several coagulation factors and lipid apoproteins that may or may not be beneficial.
Conjugated equine oestrogen (CEE) is by far the most widely used oestrogen in the USA 
but not widely used in Europe. Most of the long-term epidemiological data is with this 
formulation. It is a complex mixture containing mostly oestrone (50%) and equilin
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(25%) with small amounts of 17 hydroxyequilin, equilin, 17|E-oestradiol and 17^- 
dihydroequilenin, all in the sulphate ester form. Equilenin has pronounced hepatic effects 
and a prolonged half-life.
Greater use is made of oestradiol valerate and mixtures of oestradiol, oestrone and 
oestriol in Europe. Orally ingested oestradiol is metabolized to oestrone within the 
intestinal mucosa and liver, increasing serum oestrone concentrations. Although oestrone 
itself is a weak oestrogen it is in reversible equilibrium with oestradiol and thus acts as a 
source of oestradiol. There is a virtual absence of ovarian oestradiol secretion in 
postmenopausal women. Oestriol is not converted into oestradiol and has considerably 
less biological activity [170].
2.1.2 Paienteral Oestrogen
Oestrogen can be administered parenterally thus avoiding the first pass effect in the liver. 
Oestradiol applied to the skin in patches containing the hormone in alcoholic solution is 
absorbed into the circulation at a steady state for 3 to 4 days [171]. Oestradiol pellets can 
be implanted subcutaneously. The pellets last for several months but the rate of decline 
in serum oestradiol concentrations varies widely and can be associated with marked side 
effects [172]. Direct delivery of oestradiol into the systemic circulation can also be 
achieved by means of vaginal pessaries or rings or by topical applications of gel.
2.1.3 Combined Oestrogen and Progestogen Preparations
Due to the increased risk of endometrial hyperplasia and carcinoma with oestrogen alone 
most women who have not undergone hysterectomy are treated with a progestogen in 
addition to oestrogen. Synthetic progestogens are used as progesterone is very poorly
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absorbed even in the micronised form. It also causes somnolence in the natural form. 
Progestogens have some androgenic activity especially 19-nortestosterone derivatives 
e.g. norgestrel and norethisterone. C-21 pregnane derivatives e.g. medoxyprogesterone 
acetate, hydrogesterone, medrogestrone and megestrol acetate are very weak androgens 
[170].
To avoid the continued menstruation that usually accompanies the addition of cyclic 
progestogen therapy and oestrogen, continuous combined oestrogen and progestogen 
therapy has been introduced. It is associated with a 40% reduction in incidence of 
breakthrough bleeding especially in the first 6 months. The only organ that actually 
needs progesterone is the uterus and so providing it locally by means of a progesterone- 
impregnated intrauterine device may prove effective and avoid any systemic effects of 
progesterone.
2.2 Characteristics of Women who use HRT.
The RCGP oral contraception study cohort [173] was an observational study of 23,000 
women attending 1400 general practitioners who were using oral contraception and a 
similar number of age matched control subjects who were followed up from 1968 until 
1990. Women were followed regularly and all information on pregnancies, illnesses and 
death as well as any hormones prescribed for how long and whether the dosage was in 
accordance with the manufacturer’s recommendations. By the end of 1990 approximately 
20% of the population had used HRT, 9% were current users. This agreed with a national 
survey of prescribing habits of general practitioners carried out in 1989, which estimated 
that approximately 9% of female patients aged between 40 and 64 were using HRT [174]. 
This is much lower than the figure found in 1976 among the recruits for the American 
Nurses Health Study where 53% of postmenopausal women had used HRT. This was a
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selected population [175]. Two more recent studies carried out in UK in 1995 have 
shown an increased prevalence of use of HRT with 15-20% of women aged 45-64 now 
being current users [176] [177].
From these studies it appears that women who use HRT tend to be of higher socio­
economic or educational status. They tend to have had a hysterectomy, used the oral 
contraceptive pill in the past or to have a history of headache, migraine of nonpsychotic 
psychiatric illness. A history of ischaemic heart disease, hypertension or diabetes made 
women less likely to receive HRT therapy. The frequency of prescribing in a 1996 
review was 24.5% in all women, 21.8% in hypertensive women and only 11.1% in 
women with type 2 DM [178]. Recent prescribing figures from Ireland have shown a 
peak of prescribing of continuous combined HRT in April 2002 with 106 age adjusted 
rate per 1000 of General Medical Services population to a low of 79.6 one year later. 
[179]
2.3 Known Benefits of HRT
Possible benefits of HRT include decrease menopausal symptoms, prevention of 
osteoporosis and prevention of MI and CVA. Possible side effects include increased 
incidence of endometrial carcinoma, increased incidence of breast cancer and increased 
incidence of deep venous thrombosis and pulmonary embolism.
2.3.1 Menopausal Symptoms
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HRT is widely accepted as an effective treatment for symptoms associated with the 
menopause. Features of oestrogen deficiency e.g. hot flushes, vaginal dryness and 
atrophy of the breasts respond well to replacement. The vaguer symptoms e.g. loss of 
libido, loss of self-esteem, depression, weight gain and loss of concentration generally 
although not always seem to respond less well [180].
2.3.2 Osteoporosis.
Osteoporosis is defined as a reduction in bone mass per unit volume. Bone density 
declines with age as bone resorption exceeds new bone formation and after the 
menopause this process accelerates. Loss of ovarian function is the single most important 
factor in the aetiology of osteoporosis, but many others including white race, smoking, 
low level of physical activity, low dietary intake of calcium and vitamin D and possibly 
high dietary sodium and protein intake are also important. By the age of 70, 50% of 
women will have sustained at least one osteoporotic fracture [181]. Of those suffering a 
hip fracture up to 20% will die as a direct result and many suffer prolonged pain and 
immobility [182]. It has been calculated that HRT started early in menopause and 
continued for at least 5 years could reduce by 50% the overall incidence of osteoporotic 
fracture [183].
Oestrogen therapy protects against postmenopausal osteoporosis, no matter which 
preparation of oestrogen is used. The first evidence of the beneficial effect of oestrogen 
on the bony skeleton came from women who had undergone oophorectomy [184]. 
Oestrogen inhibits bone resorption and therefore prevents bone loss and may increase 
bone in postmenopausal women. Most studies have used conjugated equine oestrogen 
(CEE). One long term randomized study used CEE 2.5mg and lOmg of 
medoxyprogesterone acetate (MPA) for 7 days of each month lead to prevention of
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cortical, in this case metacarpal bone, loss if treatment was started 3 years after 
menopause. In the same study cortical bone was shown to increase by 8% in 10 years if 
treatment started before 3 years had elapsed [185]. The results of this study suggest that 
adding a progestogen to oestrogen therapy was not detrimental to the effect. One further 
study of progestogen alone did show some beneficial effect [186].
The daily dose of CEE required to prevent bone loss has been calculated to be 0.625mg
[187], but half of this dose may suffice when it is combined with supplemental calcium
[188]. Oestradiol valerate studies have shown a clear dose related bone protection effect
[189] and, in one trial, an increase in bone density [190]. Discontinuation of therapy is 
followed by immediate resumption of bone loss at a rate similar to that in women naive 
of the preparation [191]. Treatments with percutaneous oestradiol gel, transdermal 
oestradiol and oestradiol implants (with or without testosterone) have all been shown to 
cause gains in bone density. Once again a dose response effect is seen [192] [193] [194].
Treatment with oestrogen in postmenopausal women not only prevents bone loss but also 
prevents vertebral and femoral fractures [195] [196] [197]. From the Framingham Study 
[198] a long lasting protective effect was achieved against hip fractures when oestrogen 
was given in the first 4 years following menopause. Treatment should be continued for at 
least 5 years to obtain significant benefits in terms of reducing fracture risk. This result 
has been confirmed in computer modeling studies that predicted a 28% decrease in 
femoral neck fractures if oestrogen is given for 10 years, a 40% decrease with 15 years 
and a 55% decrease with 20 years of therapy [199]. The reduction in fracture risk 
exceeds that expected from bone density measurement [200]. It has been estimated that 
the risk of fractures increases 4 fold for each decrease of 1 standard deviation (SD) in 
bone mineral density at the hip and that 66% of femoral neck fractures occur in women 
whose BMD at the femoral neck is below the lowest quartile [201].
59
The findings of research into the effects of type 2 DM on bone mass are extensive but 
findings are inconsistent. Researchers have reported lower, equal or greater bone mass in 
people with type 2 DM relative to control subjects free from DM [202] [203] [204] [205] 
[206] [207]. The largest study has shown that bone mineral density is decreased in type 2 
DM and the level of reduction correlates with both duration of DM and the level of 
deficit in insulin secretion [208]. Bone turnover in type 2 DM with good metabolic 
control is believed to be equal to or lower than bone turnover in people without DM 
[204].
The form of treatment of DM may also be important to bone mass. Women on diet 
therapy alone have similar bone density to those without DM. In contrast women on oral 
hypoglycaemics are at higher risk (RR 1.80, 95% Cl 1.03-3.16) and women on insulin 
therapy are at even higher risk of hip fracture (RR 2.66, 95% Cl 1.52-4.64) [208]. In 
addition diabetic complications of retinopathy, neuropathy and angiopathy may influence 
the fracture event independently of bone mass [210].
Part of the inconsistency in results from trial could be caused by the heterogeneous 
groups studied (pre-menopausal vs. postmenopausal or different diabetes treatment 
groups) or by potential confounding by obesity. In animal studies longstanding insulin 
dependent DM results in osteoporosis probably related to a decrease in osteoblast 
function [34].
Women with type 2 DM may be theoretically protected from osteoporosis due to their 
tendency to obesity. This is due to the increased amount of adipose tissue producing 
metabolically active steroids and insulin related growth factors, which may stimulate 
bone formation.
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2.4 Risks of HRT
2.4.1 Endometrial Carcinoma
Endometrial carcinoma is a common gynaecological malignancy. Studies have 
investigated various endogenous and exogenous risk factors for endometrial cancer. To 
date more than 30 observational trials have confirmed that unopposed oestrogen increases 
the risk of endometrial cancer [211]. The excess risk increases with dose and duration of 
oestrogen. Ten years of unopposed oestrogen increases the risk 8.2-fold [212]. The 
increase in risk becomes apparent within 2 years of starting therapy and persists for many 
years after the preparation is stopped. The tumour induced is usually but not always 
better differentiated and less invasive and have a much better prognosis than those which 
occur spontaneously [213] [214].
The excess of endometrial carcinoma is prevented in a dose and duration dependent 
fashion by the addition of cyclic progestogen therapy [215] [216]. The duration of 
progestogen administered per cycle is of par amount importance. The administration for 
12 days each cycle of minimal quantities of progestogens prevents the development of 
endometrial abnormalities [217]. The rare endometrial cancer observed in women taking 
combined therapy (oestrogen plus a cyclic progestogen) may reflect poor compliance 
with progestogen moiety of regimen [218].
Oestrogen alone also increases the incidence of endometrial hyperplasia which is a 
premalignant condition. In a trial of 3 years of HRT 33% of women in the unopposed
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oestrogen group developed adenomatous or atypical endometrial hyperplasia. Less than 
1% of women in the oestrogen plus either MPA or micronised progestogen developed 
similar hyperplasia [138].
The association of diabetes and increased incidence of endometrial cancer has been 
reported in many studies. Increased levels of estrogen found in the serum of patients with 
DM do not give proper explanation of the phenomenon. One study [219] included 148 
patients who, due to endometrial cancer underwent surgery. The control group consisted 
of 212 patients undergoing surgery due to cervical cancer. In the case group there were 
18.9% of those with diabetes in comparison with the control group with the percentage of 
only 6.1. Ki-square test showed a statistically significant difference in the incidence of 
DM between the case (with endometrial cancer) and control (with cervical cancer) groups 
(p<0.005). Relative risk (RR) of endometrial cancer was 3.57 for patients with DM in 
comparison with those without it. From this study it appears that women with DM 
develop endometrial cancer nearly 3.6 times as often as women without it. Further data 
from the literature shows RR of endometrial cancer in patients with DM to be between 
1.3 and 2.7 [34] [220] [221].
The link between cancer and type 2 DM has been most widely studied in colon cancer. A 
population based study by Yancik et al [222] found a significant increases in colon cancer 
risk and overall mortality among patients with type 2 DM (RR1.37, 95% Cl 1.05-1.79) 
after adjustment for age, sex and tumour stage. The authors concluded that this was 
mediated through hyperinsulinaemia. Insulin has been shown to be a tumour promoter in 
animal models [223] and elevated circulating insulin and C-peptide levels have been 
related prospectively to colon cancer risk [224] [225]. In addition circulating levels of 
insulin-like growth factor I (IGF-I) which promotes cell proliferation and inhibits 
apoptosis has been positively associated with colon cancer in several studies. The
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relationship between cancer and type 2 DM is likely to be complex as while a 
hyperinsulinaemic state occurs in the early development of type 2 DM in the later stages 
â cell depletion leads to a hypoinsulinaemic state [226] [227].
2.4.2 Breast Cancer
One of the main worries regarding HRT therapy has been its association with breast 
cancer. The relationship between HRT and breast cancer is far from clear with studies 
reporting decreased, unchanged and increased risk. Results from an Oxford study [228] 
and the Nurses’ Health Study [229] do seem to have some accord. The most recent 
follow up from the Nurses’ Health Study representing 12 years follow up of 480,112 
person years of follow up has demonstrated a significantly higher risk of breast cancer 
among women currently using oestrogen than those who have never used oestrogen. No 
increase was found between those currently using HRT and those who had taken 
oestrogen but later discontinued treatment. The increased surveillance of women taking 
HRT cannot account for this finding. Combined oestrogen and progestogen is also 
associated with increased risk. Further the effect of oestrogen does not appear to depend 
on dose used or duration of treatment.
The chance of any women experiencing breast cancer during her lifetime is 1 in 9 and 
therefore even a slight increase in risk will yield a substantial increase in number of 
cancers. There is a suggestion that there is a lower mortality due to breast cancer 
associated with HRT use than that occurring spontaneously [230].
Two meta-analyses of the studies of oestrogen therapy and breast cancer have been 
carried out. The authors of the first analysis concluded that treatment of postmenopausal 
women with 0.625mg or less of CEE per day did not increase the risk of breast cancer.
63
They also concluded that the wide variation in risk in women treated with higher doses 
implied the presence of other risk factors [231]. In the second analysis the authors 
concluded that the risk of breast cancer was increased after 15 years of therapy but not 
before. This study did include pre-menopausal women and several preparations 
including oestradiol and HRT with and without progestogen. The importance of family 
history was commented upon [232]. Both analyses included case control studies only and 
cohort studies were excluded. An exponential curve fitting process was applied to the 
results which each analysis gained but this may have been flawed as short term data was 
plentiful and robust compared to any longer term data which was consequently weaker.
A third smaller and earlier meta-analysis did conclude that there was no excess risk of 
breast cancer with oestrogen replacement therapy [233].
WHI[234]
Breast density on radiographs increases in the first year of hormone therapy in 
approximately one third of women. This makes interpretation of mammograms more 
difficult [235]. Density of mammography has been found to be a marker for increased 
risk of breast cancer. Increased breast density is associated with a two-fold increase in 
risk of breast cancer [236].
Women who have had breast cancer are usually excluded from receiving oestrogen 
therapy. Small-scale studies suggest that breast carcinoma, contrary to earlier belief, may 
not be reactivated by oestrogen therapy [237] [238]. Most postmenopausal women with 
breast cancer are treated with the anti-oestrogen, tamoxifen. Tamoxifen does have some 
oestrogenic activity especially in bone and has some effects on lipoprotein metabolism.
Overall there is appears to be no apparent increased risk of breast cancer in women who 
have type 2DM. The outcome in patients diagnosed with breast cancer that have 
coexisting DM is however poorer than those without. The relative risk of death being
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1.76 (95% CI 1.23-2.52), when all other variables are removed [239]. Goodwin et al 
[240] reported on insulin levels in 512 non-diabetic women with early stage breast 
cancer. They found that the highest levels of fasting insulin were significantly associated 
with distant recurrence and death even after adjustment for BMI, age, hormonal receptor 
status and other prognostic factors for breast cancer.
2.4.3 Prothromotic Changes.
Short-term oral oestrogen alone or in combination with progestogen results in a 
procoagulant state in women without DM. The balance between pro-coagulant - 
anticoagulant shifts to increase the risk of deep venous thrombosis three fold in the first 
year of exposure [241]. A variety of thrombotic factors are noted to change. Clotting 
factors such as Factor VII rise as do markers of thrombin formation i.e. prothrombin 
fragments F I+2 and fibrinopeptide A [242]. While fibrinogen, anti thrombin and protein 
S fall [243] [244]. In addition, oestrogens may also improve platelet function [245].
Four observational studies have provided evidence for an association between 
postmenopausal FIRT and venous thi'omboembolic events (VTE). In those studies the 
risk of VTE amongst current users of HRT was 2 to 3.6 times higher than the risk in 
nonusers [246]. The absolute risk is low being 3 cases per 10,000 treated women per 
year
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2.5 HRT and Cardiovascular Risk
2.5.1 Hypertension.
Concern has been expressed regarding the use of HRT in women who have co-existing 
hypertension. Much of this concern is again based on the known association between 
high dose oestrogen containing oral contraceptives and hypertension. It is well 
recognized that there is a slight increase in blood pressure in most women taking the oral 
contraceptive pill, which adds to their relative risk for increased cardiovascular disease 
[247]. This small rise is enough to raise the blood pressure to 140/90 mmHg or more in 
approximately 5% of women during a 5-year period. In more than half, the blood 
pressure returns to normal when oral contraceptive use is stopped [248]. In a few 
women, severe hypertension occurs, leading to malignant phase hypertension and renal 
damage [249]. Although an association between malignant hypertension and the oral 
contraceptive pill is well recognized, the number of cases reported is small, and the 
clinical course and outcome of the condition in OC pill users are uncertain.
It is uncertain whether oral contraceptives directly cause hypertension de novo, or 
whether they simply exaggerate an existing propensity to develop hypertension. The 
exact mechanism of oral contraceptive-induced hypertension is uncertain, but changes in 
circulatory haemodynamics, haemorheological abnormalities, the renin-angiotensin- 
aldosterone system, insulin sensitivity and erythrocyte cation transport have been 
identified [250] [251] [252].
The situation with HRT is even less clear as menopause itself is associated with a rise in 
blood pressure which is independent of the effects of age [253]. There are only three
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published studies to date examining the effect of HRT in hypertensive women. Overall 
in two of the studies, albeit in small numbers [254] [255], systolic blood pressure fell. In 
the third study Lip et al did not find any significant change in blood pressure over a 
median follow-up of 1 Smonths in hypertensive women receiving HRT whether it was an 
oral or transdermal preparation [256]. It was concluded that HRT did not adversely 
affect blood pressure in this group of hypertensive women receiving HRT whether it was 
an oral or transdermal preparation.
2,5.2 Endothelial Dysfunction.
Oral oestradiol has been shown in women without DM to reduce PAI-1 activity by 
around 50%. This is explained in part by a reduction in PAI-1 antigen levels [257] [243] 
and also by a small increase in tissue plasminogen activator (tPA) activity. Research in 
women with DM suggests that oral oestradiol is associated with a similar fall in PAI-1 
activity [258].
Improvement in endothelial dependent vasodilatation has been observed during infusion 
of a-oestradiol into coronary arteries of postmenopausal women without DM undergoing 
angiography [259]. Oestrogen also selectively potentiates endothelial-dependent 
vasodilatation in forearm resistance vessels [260] and potentiates endothelial-independent 
vasodilatation in patients with cardiovascular risk factors [261]. This may be related to 
decreased levels of LDL-cholesterol oxidation leading to increased nitric oxide levels and 
prostocylin production and decreased endothelin levels [67] [262]. Oestrogens also have 
a calcium channel blocking effect which may help to decrease the speed of production of 
atherosclerotic plaques in coronary arteries [263]. The addition of progesterone does not
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appeal' to attenuate the beneficial effects of oral oestrogen on the endothelium and it has 
been thought it may even add to it effect [264] [265].
2.5.4 Insulin Resistance
In recent years evidence has emerged to suggest that oral HRT preparations, unlike oral 
contraceptives, do not adversely affect insulin sensitivity. Two randomised placebo 
controlled trials [266] [258] have provided promising results. Andersson et al [266] 
treated 25 women with type 2 DM with 2mg of 17j3-oestradiol for 3 months in a double 
blind crossover fashion. As well as conventional exclusion criteria (e.g. thromboembolic 
disease), patients on insulin therapy were omitted from the study. They observed 
significant reductions of around 20% in fasting glucose and a 14% reduction in HbAlc in 
the oestradiol treated group. C-peptide concentrations also fell by around 16% and there 
was a trend for an increase in whole body glucose disposal. Hepatic glucose production 
was not assessed in this study. Brussard et al [258] also examined the metabolic effects 
of 2mg 17(3-oestradiol in a similar group of patients for a shorter time period (6weeks), 
but employed a more straightforward double-blind design, and in addition excluded 
patients on metformin therapy. Nevertheless the results were consistent demonstrating a 
smaller (3.5%) but significant reduction in HbAlc. There was no effect of oestrogen 
replacement on whole body glucose disposal but suppression of hepatic glucose 
production by insulin was significantly enhanced, particularly in those patients with 
triglyceride levels less than 2.0mmol/l at baseline. In both studies weight increased 
slightly but significantly with oestradiol treatment suggesting the improvements in 
glucose metabolism was unrelated to changes in BMI.
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The two studies have also strongly suggested that unopposed oral oestradiol might 
improve glycaemic control in patients with diabetes. The predominant mechanism for 
this improvement appears to be enhancing the effect of oestradiol on insulin sensitivity in 
the liver rather than the periphery. Oral HRT preparations are likely to offer more 
pronounced effects with respect to glycaemic control than transdermal preparations. 
Consistent with this possibility, Mosnier-Pudar et al [267] observed no change in plasma 
HbAlc or fructosamine after 6 months of transdermal oestradiol therapy in women with 
DM.
In contrast to ‘natural’ oestrogen, information on the metabolic effects of conjugated 
oestrogens in subjects with DM is currently lacking. Subjects without DM some 
deterioration of glucose tolerance and increased plasma insulin concentrations have been 
seen in those receiving oral HRT containing conjugated equine oestrogen with or without 
progestogen [268].
2.5.5 Lipids
Data relating to the cardiovascular benefits of HRT had previously been derived largely 
from observational studies. These studies may have been prone to various levels of bias 
including selective use of HRT by younger healthy women with healthier lifestyles and a 
more favourable CHD risk profile [2] [76]. The studies also mainly used unopposed 
oestrogen alone. The biases in the observational studies would increase the apparent 
oestrogen benefit. A meta-analysis of 22 randomised trials of short-term oestrogen 
therapy in which cardiovascular events were given as reason to leave trial or as adverse 
events while in trial revealed a risk ratio of 1.39 in users compared to non users [269].
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This would seem to be unlikely if oestrogen reduces the risk of CVD by 30% as was 
thought from observational trials [76].
In the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial [270], 875 
postmenopausal women were recruited to receive either oral conjugated equine oestrogen 
(CEE) (0.625mg/day) alone or with medoxyprogesterone acetate (MPA) or micronised 
progesterone or placebo for 3 years. The group who received CEE alone showed a 10% 
reduction in LDL cholesterol levels when compared to the control group. The addition of 
either MPA or progestogen did not alter the effect on LDL-cholesterol levels.
In a study of 31 women by Walsh et al [271] the effect of differing doses of CEE on 
plasma lipids was examined. A dose of 0.625mg/day lead to a 15% reduction in LDL- 
cholesterol and 1.25 mg/d ay lead to a 19% reduction in LDL-cholesterol (p <0.05).
Differences between different oestrogen preparations have also been reported. McManus 
et al [272] demonstrated a 13.8% (p<0.01) reduction in LDL-cholesterol with CEE 
(0.625mg) (p<0.05) which compared to a 7.8% reduction with oestradiol valerate (Img) 
and 12.7% (p<0.05) with oestradiol (2mg) and MPA (Img). No significant effect on 
LDL-cholesterol was seen with either oestradiol (2mg) and norethisterone (Img) or 
transdermal oestradiol (50pg). All preparations were given for 4 weeks in total. In a 
longer study of 3 months of treatment LDL cholesterol levels decreased by 15% 
(p<0.001) with CEE (0.625mg) compared to 14% (p<0.005) due to oestradiol (2mg). 
Again no effect was seen with transdermal oestradiol (O.Img twice per week) [269]. 
Variations in percentages of LDL reduction between studies of HRT have also been 
attributed to differences in baseline levels in LDL cholesterol in the women recruited 
[273].
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The beneficial reductions in LDL cholesterol seen in trials are often accompanied by a 
beneficial increase in HDL cholesterol. In the PEPI trial [270] the CEE (0.625mg) group 
showed a 10% increase in HDL cholesterol during the first year of the study. The effect 
was slightly diminished over the following 2 years but remained 7% above baseline at 
completion of the trial. The addition of MPA further decreased the increase in HDL 
cholesterol to 4%. The addition of micronised progestin did not alter the effect of CEE 
alone.
Studies to examine other oestrogen preparations rather than CEE have found a similar 
effect on HDL cholesterol. The 3 month study by Walsh et al, [271] previously 
discussed, found that CEE, 0.625mg or 1.25mg, increased HDL cholesterol by 16 and 
18% respectively, while micronised oestradiol, 2mg, increased the HDL cholesterol by 
15%. Transdermal oestradiol, O.lmg per week had no effect. The McManus group also 
examined the effect of differing oestrogen preparations on HDL cholesterol levels and 
found oral oestradiol valerate (Img), CEE (0.625mg), or transdermal oestradiol 
(50[Jg/day) for 4 weeks increased the HDL cholesterol levels by 7.1% (p<0.01), 6.3% 
(p<0.05) and not significantly respectively. A substudy of this group among 18 of the 
trials participants who were non-hysterectomised demonstrated a significant fall in HDL 
cholesterol levels when norethisterone (Img) was added to the oral oestradiol (2mg). In 
contrast, the addition of MPA (5mg) to the oestradiol lead to a non significant fall in 
HDL cholesterol levels (p>0.05).
A further benefit of HRT on lipid levels is the reduction seen in lipoprotein (a) (Lp(a)) 
levels. A randomized double blind crossover study [274] of 100 women who had 
undergone hysterectomy showed a 10% reduction in Lp(a) levels after 6 months of 
treatment with oral oestradiol (2mg). After 12 months no further reduction in Lp(a) 
levels were seen. Similarly CEE (0.625mg) for 2 months lead to a 24% decrease in
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Lp(a)levels and after 6 months led to a 32% reduction in Lp(a) levels in 2 separate trials 
[273] [274]. Transdermal oestradiol (50[Jg/day, twice per week) led to a 10% reduction 
in Lp(a) levels [274]. Data from the PEPI trial showed that progestins did not effect the 
Lp(a) lowering effect of CEE [270] [277]. A combination HRT has been shown to have 
a significant (p=0.02) 16% reduction in Lp(a) levels, but only a small percentage of the 
women studies experienced a drop in their Lp(a) levels to less than 30mg/dl which is 
thought to be the critical level in CHD risk [278].
The reduction in LDL-C seen with HRT is due to up-regulation of LDL receptor numbers 
whereas the increase in HDL-C is due to increased apolipoprotein-A1 production, but is 
also due to the down regulation of lipoprotein lipase in the liver. This explains why 
topical oestrogen preparations have no effect on lipoprotein levels as hepatic first pass 
does not occur.
Several studies have shown that HRT results in an increase in triglyceride (TG) levels. A 
24% and 38% increase in total TG levels was seen in women receiving 0.625mg and 
1.25mg of CEE for 3 months. Oral oestradiol has also been shown to increase total TG 
levels by 24%. Transdermal oestradiol has not been shown to have any effect on TG 
levels [270]. Similar results were found in the PEPI trial [270] with CEE alone. The 
addition of progestins appears to have little effect on TG levels [270] [279]. In a 
retrospective subset analysis by the Menopause Study Group postmenopausal women 
with a baseline TG level of greater than 1.808mmol/l upon receiving continuous or 
cyclical CEE plus MPA experienced a 13.7% reduction in TG levels [280]. This could 
be an important finding in diabetic women who often have elevated TG levels.
With respect to lipids and lipoprotein levels in type 2 DM, results from the ARIC study, 
a large randomised controlled trial including women with type 2 DM, suggest that
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women with type2 DM have a blunted response to the HDL-raising effects of oestrogen 
(6% rise vs. 16% in control subjects) and an exaggerated hypertriglyceridaemic response 
(25% vs. 16%) [281]. Differences in LDL-cholesterol, apo A1 and apo B between 
hormone users and nonusers in diabetic and non-diabetic women were similar. These 
results were based upon cross-sectional analysis and unknown selection factors may have 
influenced the use of HRT in some women. There was no information reported on the 
formulations (conjugated oestrogens vs. natural oestradiol) and the doses used.
The lipid results from randomised trials of unopposed oestradiol in women with DM 
however have been more encouraging. These suggest that HDL-cholesterol increases by 
around 20% in women with diabetes treated with oral oestradiol [266] [282], which is a 
figure comparable to data from studies in women without DM. Furthermore the rise in 
HDL was predominantly in the cardio-protective HDL2 subtraction and, as LDL- 
cholesterol was reduced by 15-24%, the LDL; HDL ratio declined by around one third. 
Importantly triglyceride concentration increased only marginally and non-significantiy in 
both studies (3-12%), alleviating concerns arising from the ARIC study of an exaggerated 
rise in this parameter in women with DM. Indeed if anything the changes in triglyceride 
concentrations were slightly less than those seen previously in studies in women without 
DM [271] and may reflect an oestradiol-mediated enhanced suppression of hepatic 
triglyceride synthesis by insulin. That is improved insulin sensitivity similar to the effects 
on glucose metabolism. In line with the lack of change in triglyceride concentrations, 
Brussard et al observed no significant change in LDL particle size, in contrast to 
expectations. Oestradiol replacement also had no appreciable effect on the ability of 
LDL-cholesterol to be oxidised [282] [283]. There is currently no information on the 
effects of HRT in women with DM on circulating lipid peroxide and antioxidant 
concentrations.
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A previous study of a combination of transdermal oestradiol and natural progesterone in 
women with type 2 DM observed no change in plasma levels of cholesterol, HDL- 
cholesterol, triglycerides and apolipoproteins A1 and B [267].
In the Nurses Health Study [284] the beneficial effects of HRT with respect to 
cardiovascular disease in women without DM were greatest among those who used 
combined HRT when compared to women who took oestrogen alone or did not use HRT. 
Thus the addition of a progestogen which was predicted to negate some of the 
cardiovascular protection of oestrogen did not appear to do so.
A favourable change in lipoprotein profile was initially thought to be the major 
determining factor in HRT and cardiovascular risk; however it has become clear that any 
alteration in lipoprotein profile could explain only 30-50% of the potential vascular 
benefits seen with oestrogen [2].
2.5.5. HRT and Cardiovascular Trials.
In summary therefore as our study was commenced in early 1998 current understanding 
at that time was that HRT should be licensed and has proven benefit in the treatment of 
the menopause and in the prophylaxis and treatment of osteoporosis. HRT could also 
have a role to play in the prophylaxis of cardiovascular disease although this remained 
controversial. Observational studies pointed to a reduction of approximately 50% in 
cardiovascular disease in women taking HRT. Laboratory studies also identified many 
mechanisms by which HRT could have beneficial effects e.g. improving lipid profiles. 
However, there remained potential concerns regarding the potential for unmeasured 
confounding. First, women who took HRT were often healthier, better educated and also 
more likely to seek medical care. Second, epidemiological study design and
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methodology could have increased the likelihood of a favourable outcome being found. 
Further, the results of these studies were typically reported in terms of relative risk rather 
than absolute risk i.e. the likelihood of a cardiovascular event in a user was compared to 
non users rather than the likelihood of a cardiovascular event at all. This is illustrated by 
examining the results of the Nurses Health Study. This epidemiological study has often 
been cited as being a well designed study that strongly supports a CHD prevention role 
for hormones as a large number of subjects were included and the results were 
comprehensively recorded over a long time period. [284] In the 10 year follow up the 
relative risk of heart problems in users versus non users was 0.56 (after adjustment for 
age and cardiovascular risk factors) i.e. a reduction in risk of approximately 50%. 
Absolute risk was not reported but examination of the data reveals that 405 heart 
problems were reported in the 48,470 women over the 10 year period. This equates to a 
rate of heart problems of 0.12% per woman per year or approximately 1% per women 
over the 10 years in the study. From this it can be seen that 99% of the women studied 
did not have a heart problem over the 10 years whether they used HRT or not.
In addition prior to 1998 most of the epidemiological studies compared cardiovascular 
outcomes in users of HRT to non users of HRT. The effects of HRT were not compared 
to other intervention. Again this can be illustrated by the results of the Nurses Health 
Study where lifestyle interventions were statistically controlled for to avoid confounding 
rather than analysed as variables [284]. When Hu et al looked at this in the context of a 
31 %reduction in CHD among participants in the Nurses Health Study between 1982 and 
1992, HRT could account for 9% of this reduction but lifestyle changes accounted for a 
larger percentage, smoking reduction 13% and improved diet 16% and harmful lifestyle 
changes had the opposite effect, obesity raising it by 7% [285].
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The first large randomized placebo controlled trial of HRT with clinical cardiovascular 
endpoints was the Heart and Estrogen/progestin Replacement Study (HERS) was 
published in 1998 [241]. This was a secondary prevention trial. HERS randomised 2763 
menopausal women with an intact uterus, up to 80 years of age, with established coronary 
heart disease manifest as MI, CABG, angioplasty or angina with at least 50% 
angiographic narrowing of a major coronary artery to 0.625nig of CEE plus 2.5mg of 
MPA daily or placebo. The primary outcome measure was the combination of nonfatal 
MI and coronary death. At the end of 4.1 years of follow up, despite the predicted 
favourable fall in LDL-c concentration and rise in HDL-c concentration there was no 
difference in the primary outcome in the active group when compared to the placebo 
group (172 events in treatment group, 176 in placebo group).
The HERS investigators concluded that this HRT regimen did not reduce overall 
coronary risk in women with established CHD and noted a trend toward an early increase 
in risk (RR1.52) and a possible later decrease (RR 0.75) although the Cl over this time 
period was wide and ranged over 0 (0.50-1.13). To ascertain if the possible coronary risk 
reduction seen in yeai'S 4-5 of the HERS trial would persist and possibly lead to an 
overall decrease in the risk of CHD in the treatment group an open labeled event 
surveillance study was carried out on 93% of the HERS participants who completed the 
trial and wished to continue on with HRT (HERS II). This extended the total mean 
observation time to an average of 6.8 years. At the end of this study again no significant 
difference in CHD events was observed in the HRT group compared to the placebo 
group. Adjustments for potential confounders including statin use and selective analysis 
of women adherent to randomized treatment assignment did not produce significant 
differences in outcome [286].
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Concern was expressed by the HERS investigators over a 2.08-fold increase in venous 
thromboembolism and a 40% excess of gall bladder disease requiring surgical 
intervention. Given the lack of CHD benefit this level of harm becomes even more 
important. Paiadoxically the HERS investigators found a decreased incidence of 
diabetes in the HRT arm of the study (6.2% HRT group vs. 9.5% in the placebo group). 
The relative hazard of diabetes in the HRT group was calculated as 0.65 (95% Cl 0.48- 
0.89). This remained unchanged after adjusting for baseline demographic characteristics 
and laboratory and medication variables. The number of patients needed to be treated 
with CEE+MPA to prevent one case of incident DM was 30(95%CI 18-103) [287]. Any 
benefit from this would need to be weighed against the adverse events seen by the 
investigators.
Confirmation of the HERS results from a number of other secondary CHD prevention 
studies then began to appear. These included:
1. The Papworth HRT Atherosclerosis Study (PHASE) [288] which randomized 225 
menopausal women with established CHD to transdermal oestrogen plus 
progestin versus placebo. No evidence for cardiac prevention was seen. A non 
significant increase in coronary events was seen in the HRT group with event 
rates highest in the 2"  ^and 4^*^ years of the study. Each year a nonsignficant 
increase in DVT was also seen for women in the HRT group.
2. The Estrogen Replacement and Atherosclerosis (ERA) angiographic trial 
[289] randomized 309. women mean age 66 years to CEE or placebo if they had 
previous hysterectomy and CEE plus MPA or placebo if not. Coronary 
angiograms were canied out at baseline and after 3.2 years of treatment. No 
difference in angiographic regression or progression was seen in the HRT versus 
placebo groups.
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3. Women’s Angiographic Vitamin and Estrogen (WAVE) trial [290] randomized 
423 women with at least 15-75% coronary stenosis at baseline angiogram to CEE, 
CEE plus MPA or placebo dependent on hysterectomy status and Vitamin C plus 
E versus placebo in a 2-by-2 factorial design. Follow up was for 2.8 years and at 
this time repeat angiograms showed nonsignificant worsening of the coronary 
arteries. Additionally in the HRT group there was a significant increased risk of 
death and nonfatal MI and a trend to an increase in risk in the Vitamin treated 
group.
4. The Estrogen in the Prevention of Reinfarction Trial (ESPRIT) [291] randomized 
1017 women aged 50-69 who were post MI to oestradiol or placebo and followed 
them for 2 years. No difference in reinfarction, cardiac death and all cause 
mortality was seen but 50% of HRT group failed to comply with study mediation 
and 37% of the control group started on HRT.
5. The Women’s Estrogen-progestin Lipid Lowering Hormone Atherosclerosis 
Regression Trial (WELL-HART) [292] randomized 226 women with documented 
CHD to 17 p oestradiol plus sequential MPA or placebo. Mean age of 
participants was 63. The women had their LDL-cholesterol level reduced to 
below 130mg/dl with a combination of diet plus statin therapy and a baseline 
angiogram was carried out. The women were then followed up for an average of
3.3 years and repeat angiograms performed. No significant effect on progression 
or regression of coronary atherosclerosis was seen in the treatment group when 
compared to the placebo group.
In 2002 as our study was concluding another pivotal clinical trial on the role of HRT in 
cardiovascular disease prevention was reported [234]. This was a primary prevention 
trial which was planned to run until 2005. It was stopped early after 5.2 years of follow 
up due to health safety concerns, i.e. an increased risk of invasive breast cancer that
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exceeded the preset trial stopping boundaries, in addition to a lack of global risk benefit, 
again based on a pre-established global risk score. This was one arm of the Women’s 
Health Initiative Trial (WHI). This arm of WHI randomized 16,608 women aged 50-79 
with an intact uterus to 0.625mg of CEE plus 2.5mg of MPA or placebo. The trial was 
stopped due to a 26% (95% Cl of HR 1.00-1.59) increased risk of breast cancer. Other 
results included a doubled risk of PTE (95% Cl of HR 1.39-3.25), a 29% increased risk 
of CHD (95% Cl of HR 1.02-1.63 and a 41% increased risk of CVA (95% Cl of HR 
1.07-1.85), Benefits seen included a 37% decreased risk of colon cancer a 33% 
decreased risk of hip fracture and a 24% decreased risk of total fracture. No effect was 
seen on all cause mortality. In clinical terms this would equate to for every 10, 000 
treated for 1 year with HRT an anticipated 7 further CHD events, 8 further strokes, 8 
PTE, 8 invasive breast cancers with 6 fewer colon cancers and 5 fewer hip fractures. 
From this it can be seen importantly that breast cancer, CHD, CVA and PTE provide 
almost equal contributions to harm from HRT. The investigators based on these results 
concluded that HRT should not be recommended for the primary prevention of CHD.
Subsequent analyses of the results have shown that most of the excess CHD risk was of 
MI rather than angina, revascularisation or heart failure. The excess risk was most 
apparent (as in the HERS study) in the first year of the trial. The group most at excess 
risk of MI during this time was the youngest cohort of women aged 50-59 years [293].
Subsequently tlie oestrogen only arm of WHI was also prematurely halted due to health 
safety concerns and a lack of benefit in 2004 (planned to run to 2005). Follow up of 
10,739 women with hysterectomy for 6.8 years with 0.625mg of CEE or placebo had 
shown no effect on risk of CHD, with an increase in CVA risk similar to that seen in the 
CEE/MPA arm of the trial i.e. 12 more CVA for every 10,000 women treated for 1 year.
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There was a decreased risk of hip fracture (RR 0.61), a non significant decrease in breast 
cancer risk (RR 0.77) and a nonsignifieant decrease in risk of colon cancer (RR 1.08)
Thus, over the time of our investigations of HRT in diabetes, the evidence for a role for 
HRT in the prevention of CHD had altered dramatically. At the inception of our trial, 
HRT seemed, based on observational data and animal studies, to have much to offer 
women in both primary and seeondary prevention of CHD especially in women with 
increased risk of CHD e.g. women with T2DM. However, around the time of its 
completion, randomized controlled trials had indicated that HRT should not be 
commenced or continued for either primary or secondary prevention of CHD. The latter 
advice is now widely accepted by all national bodies. Women at increased risk for CHD 
should be given conventional CHD risk reducing agents, and there is not role whatsoever 
presently for hormonal preparations in CVD risk reduction.
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CHAPTER 3
PILOT STUDY
3.1 Introduction
An open label pilot study of Kliofem, a continuous combined HRT of oestradiol 2mg and 
norethisterone Img was carried out on 10 postmenopausal women recruited from a 
general diabetic clinic. This was carried out to allow power calculations to be carried out 
for the main study and also to assess the side effect profile in our chosen group of 
patients.
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3.2 Methods
3.2.1 Patients Recruited
Ten postmenopausal women with type 2 DM were recruited from the general diabetic 
outpatient clinics at Glasgow Royal Infirmary University NHS Trust to the pilot study. 
The inclusion and exclusion criteria were as for the main study.
Patients were included regardless of their treatment for diabetes whether it was diet, oral 
hypoglycaemic agents or insulin.
The ethics committee of the Trust approved the study and all women gave informed 
consent prior to entry into the study.
This was a non-blinded non-randomised study of the oral continuous combined HRT 
preparation Kliofem (oestradiol 2mg, norethisterone Img) carried out over a 6-week 
period.
Anthropometric measurements and fasting blood samples for lipoprotein and metabolic 
parameters were obtained at baseline and after 6 weeks of therapy.
3.2.2 Laboratory Analysis
The reproductive hormones: oestradiol, luteinising (LH), follicle stimulating hormone 
(FSH), testosterone and sex hormone binding globulin (SHBG) were measured using
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semi-automated Tmmulite’ technology (DPC, Los Angeles, USA). Plasma total 
cholesterol, triglyceride, LDL-cholesterol and HDL-cholesterol were determined by a 
modification of the standard Lipid Reseaich Clinics Protocol. The intra-assay and inter­
assay coefficients of variation (CVs) for lipid measures were both less than 3%. 
Fibrinogen, factor VII and factor IX, activated protein C (APC) ratio and tissue 
plasminogen activator (t-PA) antigen were measured in citrated plasma (0.11 M 
trisodium citrate; 9:l:vol:vol) as previously described [294][295] [296]. The APC ratio 
measurement was an APTT-based test rather than a factor-V prediluted test. The intra­
assay CVs for these haemostatic mediators were all less than 5%. C-peptide was 
measured using the DPC Immulite 2000 analyser with a CV of <7%. Plasma glucose was 
measured using the glucose oxidase method (Glucose Reagent Kit - Olympus AU5200, 
Olympus Optical Co Ltd).
C-reaetive protein concentration was measured using an in-house sensitive double 
antibody sandwich ELISA as described previously [297]. The assay was linear up to 
5mg/1 and logarithmic thereafter, and had a lower detection limit of 0.10 mg/1. The inter- 
and intra-assay coefficients of variation were less than 10% across the range of measured 
results. Sensitive IL-6 was measured by double antibody sandwich ELISA (R & D 
systems) with an intra-assay CV of 8%.
3.2.3 Statistical Analysis
Both parametric and nonparametric tests were used to assess differences from the 
baseline. Nonparametric testing was applied to triglyceride, VLDL-Cholesterol and 
leptin results, as these were not normally distributed unlike the other results.
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3.3 Results
The baseline values and the effects of treatment on insulin resistance, lipids, lipoprotein 
profile, fibrinolysis, leptins and androgens are shown in tables 3 .1-3.4 respectively.
Mean age of patients at inclusion was 59. Two patients were on metformin, 3 on 
gliclazide/ glibenclamide and 2 were on diet therapy. The average mean BP was 
120mmHg. Mean duration of diabetes was 3 years and of menopause was 9 years. 
Vaginal bleeding led to the withdrawal of 3 patients prior to completion of 6 weeks of 
treatment and they were excluded from any further analysis. Compliance was assessed by 
measurement of plasma oestradiol levels, which were on average 349pmol/l (range 140 to 
700pmol/l).
No significant differences were found in the body mass index or blood pressure either 
systolic or diastolic during the time on treatment or until washout measurements were 
made. The body mass index decreased by 0.5% during treatment and continued to fall 
during the washout period. Neither decrease reached a significant level. The waist to hip 
ratio and blood pressure levels fell, but again the change did not reach significance.
The levels of H bA lc and C peptide decreased by a significant amount during the time on 
treatment (p=0.02, p=0.05 respectively). This was not sustained off treatment.
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Table 3.1
Baseline Characteristics/Insulin Resistance in Pilot Trial
Baseline 6weeks washout p treatment p washout
BMI(Kg/m2) 30.04(4.98) 29.98(4.52) 29.77(4.9) 0.9 0.4
Waist:hip ratio 0.79(0.11) 0.82(0.09) 0.85(0.09) 0.2 0.2
Systolic BP(nnnHg) 120(14) 117(9) 116(14) 0.49 0.31
Insulin/Glycaemia
H bAlc 8.73(1.57) 7.82(1.93) 8.21(1.81) 0.02 0.2
C peptide 1.22(0.35) 0.99(0.99) 0.98(0.41) 0.05 0.16
Table 3.2
Lipids
Baseline 6weeks washout p treatment p washout
Cholesterol (mmol/1) 5.4(1.82) 4.79(1.34) 5.21(1.68) 0.05 0.4
LDL-C (mmol/1) 3.61(1.4) 3.34(1.13) 3.35(1.39) 0.4 0.35
HDL-C (mmol/1) 0.95(0.25) 0.89(0.15) 1.06(0.22) 0.25 0.05
LDL/HDL 3.91(1.66) 3.72(1.09) 3.57(1.67) 0.67 0.22
Tri glyceride(mmol/l) 2.34(1.17) 1.97(0.83) 2.07(0.82) 0.09 0.4
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Table 3.3
Haemostatic Indices
Baseline 6weeks p treatment
Factor VII (lU/dl) 175(45.3) 135.7(30.9) 0.001
Fibrinogen (g/1) 3.51(0.51) 3.72(0.59) 0.1
vWF 153.9(50.6) 142(49.3) &22
Leptin 24.55(14) 22.55(10.5) 0.93
Table 3.4
Androgens
Baseline 6weeks washout P
treatment
P
washout
Testosterone 1.71(0.41) 1.41(0.55) 1.49(0.52) 0.07 0.33
FAI 7(A3) 4.4(3.4) 6.6(4.4) 0.03 0.57
Total cholesterol levels fell to a significant degree while on treatment (p-0.05). This is 
seen to be a result of the cumulative fall in LDL-cholesterol, HDL-cholesterol and 
VLDL-cholesterol all of which were seen to fall but levels did not reach conventional 
research significance of 0.05. VLDL-cholesterol did fall to a significance of p=0.1. The 
same level of significance was seen in the level of fall of triglyceride levels. These 
changes were not sustained off treatment. In contrast HDL-cholesterol levels rose 
significantly after treatment was discontinued (p=0.05). Ratio of LDL/HDL-cholesterol 
did not change significantly over either period in the study.
Factor VII levels fell by 22.5% during treatment (p=0.001). No correlation between the 
fall in factor VII levels and triglyceride levels was found. Fibrinogen levels rose to some 
degree of significance (p=0.1). Leptin and von Willebrand factor levels did not change to 
a significant degree during treatment.
Free androgen index decreased significantly while on treatment (p=0.03) compared to off 
treatment when no significant reduction was found. Testosterone also decreased while on 
treatment but not to such a degree of significance.
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3.4 Discussion
This study demonstrated that in the short term, in a small number of patients, an oral 
combined HRT preparation resulted in an improvement in control of type 2 diabetes as 
indicated by the decrease in HbAlc and C peptide. The fall in HbAlc and C peptide of 
10% and 19% respectively are in line with studies carried out previously in 
postmenopausal women with type 2 diabetes using oestradiol alone [282] [266].
The waist to hip ratio was seen to rise in this study while on HRT therapy. The BMI in 
contrast fell during the study. However neither result reached significance.
The lowering of the total cholesterol reflects the lowering of LDL-cholesterol. This is 
thought to be due to oestrogen induced up regulation of LDL receptors in the liver. The 
drop in LDL -cholesterol in this sample did not reach significance. The fall in HDL- 
cholesterol while on treatment was balanced by the fall in LDL-cholesterol as indicated 
by the non-significant fall in the LDL/HDL-cholesterol ratio. The rise anticipated in 
HDL-cholesterol from studies in non-diabetic women was not seen. The results we 
observed were a balance of the oestrogenic increase in HDL-cholesterol and the 
progestrogen induced reduction in HDL-cholesterol. The more androgenic norethisterone 
is seen to predominate. The observed change in HDL-cholesterol may also reflect 
observations in the ARIC study that in diabetic women the oestrogenic response is 
blunted [281].
Oestrogens are known to increase triglyceride, and in turn, VLDL-cholesterol synthesis. 
However androgenic progestogens antagonise this effect and reduce triglyceride synthesis 
in the liver. This response is seen to predominate in our study. The results observed did
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however allay our eoncerns regarding the hypertriglyceride response experienced in 
previous studies [281].
The changes in factor VII levels seen in our study are not as anticipated. Factor VII is 
widely associated with CHD and in the HERS study the observed early increased risk of 
CHD events was thought to be due to an immediate prothrombotic effect [241]. This 
effect was likely to be due to a rise in Factor VII and fibrinogen. Wliile a rise in 
fibrinogen of some significance was seen, the factor VII levels were seen to fall to a 
greater extent. No correlation was found between the fall in triglyceride and factor VII 
levels
This study revealed that HRT was safe for short-term use in postmenopausal women with 
type 2 DM. The high dropout rate allowed us to make some changes to our study design 
in particular a lower dose preparation was chosen to lessen the side effects experienced 
by participants.
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3.5 Power Calculations
From the pilot study it was known that the minimum clinically significant difference for 
changes in LDL-cholesterol was O.38mmol/I. Large studies into oestradiol replacement 
therapy have shown that the standaid deviation of changes in LDL-cholesterol are 
approximately 0.48mmol/l. For the main study an 80% probability of detecting the above 
difference at a 5% significance level was required. Calculations using these figures 
revealed a standard difference of 1.26. Tables were then used to calculate that 36 
patients would be needed for the study i.e. 18 patients in each group. A drop out rate of 
20% was allowed for (as this had been the figure seen in the pilot study) and so it was 
anticipated that 44 patients in total would need to be recruited to allow the main study to 
have the strength required to show a significant difference in LDL-cholesterol the main 
outcome measure.
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CHAPTER 4
METABOLIC, INFLAMMATORY AND HAEMOSTATIC EFFECTS
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4.1 Introduction
Until the publication of the Heart and Oestrogen/Progestogen Replacement Study 
(HERS) [241] and more recently of the Women’s Health Initiative (WHI) study [234], 
many women and their physicians were convinced of the cardio-protective effects of 
Hormone Replacement Therapy (HRT). In HERS, women with established CHD were 
randomised to 0.625 mg/d conjugated equine oestrogen (CEE) plus 2.5 mg/d medroxy­
progesterone aeetate (MPA)) or matching placebo. The HRT group experienced an 
elevation in coronary heart disease (CHD) risk in the first year of use and no overall 
difference in events over four years [241]. The WHI used the same prepaiation in a 
primary prevention setting and also reported an increased risk of CHD and of stroke in 
the active arm compared to placebo [234], and more recently a potential deleterious effect 
on cognitive function [287]. Therefore, despite a beneficial effect of this preparation on 
LDL and HDL cholesterol concentrations, other effects may be unfavourable; the search 
for these is receiving intense scrutiny. Most cuixent attention has focused on possible 
triglyceride-raising, pro-coagulant and pro-inflammatory effects of CEE and 2mg 
oestradiol containing HRT’s [299] [243] [300] [244] [301] [302] but data on preparations 
containing low dose oestradiol combined to norethisterone, particularly from randomised 
placebo-controlled trials, are sparse.
Women with type 2 diabetes have a markedly elevated baseline risk for CHD. A recent 
report from a prospective observational study [303] suggested that HRT use leads to a 
significantly increased risk of death from all causes and ischaemic heart disease among 
women with diabetes. Current users of HRT with diabetes had a near ten-fold increased 
risk of myocardial infarction (9.2, 95% Cl, 2.0 to 41.4) compared with never users with
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diabetes. By contrast, Ferrera et al [304] noted that among women with diabetes who did 
not have a reeent myocai'dial infarction, current HRT use was associated with a 
significant 16% lower risk of acute myocardial infarction. Thus HRT effects on CHD 
risk in diabetes are controversial and randomised trials are required.
HRT preparations are not homogeneous with respect to metabolic effects: metabolic 
actions are profoundly altered according to route of delivery, dose and chemical nature of 
the combined oestrogenic and progestogenic preparations [305], Data from trials with 
differing designs suggest that lower doses of oestradiol (Img) or transdermal preparations 
may have fewer deleterious and perhaps even beneficial effects on inflammatory and 
haemostatic pathways [302] [306][307] [301][308]. In addition, there is an increasing 
awareness that androgenic progestogens such as norethisterone may offer several 
advantages over MPA particularly with respect to coagulation and inflammatory 
parameters [307] [308].
The aim of the present randomised double-blind placebo-controlled study therefore was 
to examine the metabolic effects of a novel continuous combined preparation containing 
Img oestradiol and 0.5 mg norethisterone in women with type 2 diabetes. We 
comprehensively assessed key pathways, including lipids and glycaemic parameters, and 
haemostatic and inflammatory pathways, known to be influenced by hormonal regulation 
and relevant to CHD risk. The hypothesis was that this low dose oestradiol preparation 
combined with norethisterone would continue to reduce LDL-cholesterol, limit any 
triglyceride rise and would have fewer potentially adverse effects on key coagulation and 
inflammatory parameters than observed with conventional CEE/MPA-based preparations.
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4.2 Methods
4.2.1 Subjects Recruited
From December 1998 to September 2000, 50 women with type 2 diabetes aged under 70 
years of age were recruited from general diabetic clinics in Glasgow Hospitals. Women 
randomised were clinically and biochemically postmenopausal i.e. at least one year since 
last menses and a follicle stimulating hormone (FSH) concentration of greater than 20 
IU/1. Menopause could be either natural or surgically-induced. A normal pelvic 
examination and mammogram within the year prior to inclusion in the trial was also 
required.
Exclusion criteria comprised: poor glycaemic control; severe hypertri gl y ceridaemi a (>10 
mmol/1); moderate to severe hypertension (systolic >160 mmHg, diastolic >110 mmHg); 
renal impairment (serum creatinine greater than twice the upper limit of normal range); 
liver disease (serum transaminases and bilirubin greater than twice the upper limit of 
normal range); or established cardiovascular, cerebrovascular, or peripheral vascular 
disease. Subjects with either a personal history of - or first-degree relative with - breast 
cancer were excluded.
Women eligible at screening were randomised to prescription of either active medication 
(Img oestradiol plus 0.5mg norethisterone) or identical placebo daily for six months. 
Randomisation was effected in blocks of four using computer-generated numbers. 
Compliance was assessed by returned medication packs at the final visit and by oestradiol 
and gonadotrophin concentration measures at the final visit. A requirement of oestradiol 
to rise by more than lOpmol/1 and FSH to decline by more than 5 U/L was pre-defined.
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The paiticipating hospitals’ local research ethical committees granted approval. All 
subjects gave written informed consent to a single investigator (JM). As far as possible, 
existing medications for glycaemic control, blood pressure or lipid lowering (detailed in 
Table 4.1) were not altered throughout the course of the study.
We determined that our sample size had 80% power to detect a 5% reduction in LDL- 
cholesterol and 90% power to detect a 5% reduction in factor VII with a=0.05.
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Figure 1 : Trial Outcome Flow Chart
Assessed for elisibilitv
Randoiiiised (n=50)
Lost to follow-up (n=l )
Did not continue intervention (n=2)
Analysed (n=23)
Excluded from primary endpoint
Allocated to HRT (n=25) 
Received HRT (n=25)
Did not receive HRT (n-0)
Allocated to placebo (n=25) 
Received placebo (n=25)
Did not receive placebo (n=0)
Completed (n=22)
Did not demonstrate compliance (n=3) 
Excluded from primary endpoint
Lost to follow-up (n=l)
Did not continue intervention (n=l)
Excluded (n=8)
> high H bA lc(n=3),
> abnormal LFT's (n=2)
>  abnormal mammogram (n=2)
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Table 4.1.
Baseline characteristics of study groups. Mean (SD) reported.
Active Placebo
Age (years) 60.7 (5.5) 61.3 (4.8)
BMI (Kg/m^) 30.5 (6.5) 29.8 (5.61)
Waist circumference (cm) 93.9(11.3) 93.7 (13.6)
Years post menopausal 14.6 (8.5) 14.2 (6.3)
Smokers (Y/N) 6/19 5/22
Systolic blood pressure (mmHg) 152(17) 151 (21)
Diastolic blood pressure (mmHg) 87(8) 83(9)
Medications
Diet alone (n) 5 3
Oral hypoglycaemics (n) 10 11
Insulin (n) 4 9
Anti-hypertensives (n) 10 10
Lipid-lowering agents (n) 5 5
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4.2.2 Study visits
Women attended the Diabetes Centre, Glasgow Royal Infirmary, Glasgow at baseline and 
6 months, having fasted for 10 hours and avoided heavy exercise, alcohol and caffeine in 
the preceding 24 hours. Subjects rested prone for 15 minutes prior to blood pressure 
recordings being taken in triplicate (mean recorded). The women also had anthropometric 
measurements to include height (cm), weight (kg), and waist and hip circumferences 
(cm). From these body mass index (BMI) was calculated as weight/(height)^ in kg/m^, as 
well as waist to hip ratio (WHR).
4.2.3 Laboratory methods
The reproductive hormones; oestradiol, luteinising (LH), follicle stimulating hormone 
(FSH), testosterone and sex hormone binding globulin (SHBG) were measured using 
semi-automated Tmmulite’ technology (DPC, Los Angeles, USA). Plasma total 
cholesterol, triglyceride, LDL-choIesterol and HDL-choIesterol were determined by a 
modification of the standard Lipid Research Clinics Protocol. The intra-assay and inter­
assay coefficients of variation (CVs) for lipid measures were both less than 3%. 
Fibrinogen, factor VII and factor IX, activated protein C (APC) ratio and tissue 
plasminogen activator (t-PA) antigen were measured in citrated plasma (0.11 M 
trisodium citrate; 9:1 :vol:vol) as previously described . The APC ratio measurement was 
an APTT-based test rather than a factor-V prediluted test. The intra-assay CVs for these 
haemostatic mediators were all less than 5%. C-peptide was measured using the DPC 
Immulite 2000 analyser with a CV of <7%. Plasma glucose was measured using the 
glucose oxidase method (Glucose Reagent Kit - Olympus AU5200, Olympus Optical Co 
Ltd).
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C-reactive protein concentration was measured using an in-house sensitive double 
antibody sandwich ELISA as described previously [308]. The assay was linear up to 
5mg/l and logarithmic thereafter, and had a lower detection limit of 0.10 mg/I. The inter- 
and intra-assay coefficients of variation were less than 10% across the range of measured 
results. Sensitive IL-6 was measured by double antibody sandwich ELISA (R & D 
systems) with an intra-assay CV of 8%.
4.2.4 Statistical analysis
Mean differences in changes from baseline between the two treatment groups were 
compared using the unpaired t-test: the 95% confidence interval for change in active 
group data relative to change in control group data are presented. Adjustment for baseline 
concentrations was made by linear regression. Baseline data are presented as mean and 
SD or median and interquartile range (IQR) for parameters exhibiting skewed 
distribution.
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4.3 Results
4.3.1 Subjects recruited
58 women were screened as potential recruits into the study. Of these, 50 were 
randomised (Figure 1). The eight women not entered had unacceptably high HbAlc 
(n=3), abnormal liver function tests (n-2), abnormal mammogram (n-2) or abnormal 
pelvic examination (n=l). Five women did not complete the study due to either relocating 
or personal reasons. Thus, 45 women completed the study. Of the 22 in the active gi'oup, 
19 demonstrated adherence to study medications by predetermined criteria. Data from 
women falling outside these criteria were omitted from subsequent analyses. There were 
no serious adverse events. Breast tenderness and breakthrough bleeding were reported by 
three women on active treatment and by none on placebo.
Table 4.1 demonstrates the baseline characteristics of women completing the study. The 
two groups allocated to treatment were similar in age, BMI, blood pressure and years 
since menopause. All categories of diabetes therapy were represented and similar 
percentages were taking anti-hypertensive or lipid-lowering agents. The treatment groups 
also showed similar baseline hormonal and lipid concentrations (Tables 4.2 and 4.3)
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Table 4.2.
Sex hormone changes in active and placebo groups. Baseline data are given as mean
(SD) or median (interquartile range).
Active
Baseline
Mean
Change
Placebo
Baseline
Mean
Change
'“'Difference 
(95% Cl)
P
LH (IU/1) 35 (26-39) -23.7 37 (24-44) -0.4 -23 (-32 to - 
15)
<0.001
FSH (IU/1) 53 (49-83) -41.8 60 (48-81) -2.5 -39 (-50 to - 
28)
<0.001
Oestradiol
(pmol/1)
63.3(15.9) +165 65.4 (14.6) 2.0 163 (111 to 
215)
<0.001
Testosterone
(nmol/1)
1.23 (0.63) -0.12 1.19(0.33) 0.0 -0.12(-0.42 
to 0.17)
0.41
SHBG 33 (21-52) +15.7 37 (27-49) +1.4 14.3 (0.52 to 
28.1)
0.042
LH = luteinising hormone, FSH -  follicle stimulating hormone, SHBG= sex hormone 
binding globulin 
difference is change active relative to change in placebo
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Table 4.3
Lipids and insulin/glycaemia changes in active and placebo groups. Baseline data are
given as mean (SD) or median (interquartile range).
Active
baseline
Mean
Change
Placebo
baseline
Mean
change
Difference P
Cholesterol
(mmol/1)
6.02(1.07) -0.62 5.68 (0.97) -0.13 -0.49 (-0.05 to 
-0.90)
0.020
LDL-C
(mmol/1)
4.14(0.93) -0.55 3.80(1.00) -0.10 -0.44 (-0.79 to 
-0.08)
0.018
HDL-C
(mmol/1)
1.30 (0.32) -0.07 1.36 (0.29) -0.06 0.01 (-0.10 to 
0.10)
0.83
Choi: HDL-C 
ratio
4.88 (1.58) -0.28 4.46(1.53) +0.20 -0.48 (-0.99 to 
0.00)
0.05
Triglyceride
(mmol/1)
1.75 (1.15- 
2.35)
-0.034 1.68 (1.25- 
2.21)
+0.16 -0.19 (-0.58 to
0.19)
0.31
C-peptide
(nmol/1)
0.97 (0.65- 
1.29)
-0.18 0.79 (0.49-
1.51)
0.09 -0.27 (-0.44 to 
-0.09)
0.003
Glucose
(mmol/1)
12.4 (4.2) -1.74 11.3 (3.2) 0.42 -2.16 (-4.06 to 
-0.28)
0.026
HBAlc(%) 10.2(1.8) -0.37 10.2(1.3) 0.22 -0.59 (-1.45 to 
0.27)
0.17
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4.3.2 Sex Hormone Changes.
A significant reduction in gonadotrophin concentrations and an elevation in oestradiol (all 
P<0.001) and sex hormone binding globulin (SHBG) levels (P=0.042) was observed in 
those women randomised to active therapy as a group (Table 4.2). Total testosterone was 
not altered significantly but free androgen index fell significantly (p<0.001, data not 
shown).
4.3.3 Lipid and Insulin/Glycaemic Changes
Table 4.3 demonstrates Lipid and glycaemic changes in the groups. Both total (10%) and 
LDL cholesterol (13%) concentrations were reduced significantly with active treatment 
(p<0.05) but HDL cholesterol and triglyceride were not altered. Similarly, fasting C- 
peptide was reduced by 19% (p<0.01 vs change in placebo). Fasting glucose was also 
reduced (p<0.05) in the active arm as was H bA lc but the latter change did not reach 
significance (p>0.10).
4.3.4 Haemostatic and Inflammatory Changes
Haemostatic and inflammatory variables are presented in Table 4.4. Significant 
reductions in Factor VII levels (p<0.001), and t-PA antigen and IL-6 concentrations 
(p<0,02) were observed without significant alteration in factor IX, APC resistance (APC 
ratio), fibrinogen or CRP concentrations.
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Table 4.4
Haemostatic and inflammatory changes in active and placebo groups. Baseline data are
given as mean (SD) or median (interquartile range).
Active
baseline
Mean
Change
Placebo
Baseline
Mean
Change
Difference P
Factor VII 
(lU/dl)
160 (36) -26.7 152(31) 5.50 -32 (-43 to -21) <0.001
Factor IX 
(lU/dl)
163 (42) +7.00 155 (40) +3.60 3.7 (-9.9 to 
16.3)
0.49
APC Ratio 2.74 (0.6) +0.25 2.74 (0.5) +0.23 0.0 (-0.25 to 
0.25)
0.99
tPA-antigen
(ng/ml)
14.9 (5.6) -2.01 12.7 (3.8) +0.97 -2.98 (-5.00 to - 
0.95)
0.005
Fibrinogen
(g/1)
3.91 (0.68) +0.02 3.89 (0.92) -0.12 0.14 (-0.19 to 
0.47)
0.39
CRP
(mg/1)
5.05 (4.46- 
8.53)
+1.45 3.37 (1.76- 
8.10)
+0.72 0.73 (-2.27 to 
3.72)
0.62
IL-6 (pg/ml) 3.46 (2.48- 
4.89)
-0.32 3.55 (2.11- 
4.47)
+1.10 -1.42 (-2.55 to- 
0.29)
0.015
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Significance values were also checked with adjustment for baseline concentrations of all 
parameters measured. The results were in keeping with unadjusted values: specifically, 
reductions in cholesterol (adjusted p=0.032), factor VII (adjusted p<0.001), tPA-antigen 
(adjusted p=0.01) and IL-6 (adjusted p=0.045) were similar and CRP remained similarly 
unchanged (adjusted p-0.96).
Finally, we determined the number of patients randomised to HRT or placebo that 
achieved 10% decline in LDL cholesterol and factor VII concentration using an intention 
to treat analysis. A 10% decline is either parameter in clinically relevant. Ten of the 25 in 
the HRT group had >10% decline in LDL cholesterol compared to only 4 in the placebo 
group (p=0.059, Chi-square test). For factor VII, 16 of the 25 in the HRT group had 
>10% decline in factor VII whereas only 1 of the 25 in the placebo group did so 
(P<0.0001).
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4.4 Discussion
Our study is one of the very few randomised double-blind placebo-controlled trials of 
HRT in diabetic women, albeit in an older group than those who would normally receive 
HRT. More importantly, it is the largest study to date to examine metabolic actions of a 
novel continuous combined preparation containing Img oral oestradiol and 0.5mg 
norethisterone in a high CHD-risk population. The key results were lowered plasma LDL 
cholesterol, Factor VII, t-PA antigen and IL-6 concentrations, and statistically similar 
triglyceride, Factor IX, APC resistance and CRP levels. This pattern of effects differs 
markedly from the profile produced by normal dose HRT containing CEE and MPA used 
in HERS and WHI which increase triglyceride, factor VII and promote a doubling in CRP 
concentrations [241] [299]. As a result, an HRT containing low dose oestradiol and 
norethisterone may be more suitable for women who have an elevated risk of CHD (e.g. 
those with type 2 diabetes), who require HRT for menopausal symptom relief or bone 
protection. Formal clinical trials are required to test this suggestion.
The potentially better portfolio of metabolic effects of the HRT in this study may result 
either from the use of a low oestradiol dose or from the use of a more androgenic 
progestogen, norethisterone. More likely is that the balance of effects deriving from this 
HRT lean more towards androgenic rather than oestrogenic actions. This is an important 
point since conventional wisdom has dictated the use of non-androgenic progestogens to 
minimise any HDL-cholesterol reducing effect [299]. Clearly, this course of action needs 
re-evaluation as HDL-cholesterol was unchanged in the present study.
With respect to the inflammation cascade, HRT’s containing 2mg oestradiol or CEE 
elevate CRP concentrations almost two-fold [300] [294]. In the observational arm of the
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(large) WHI, current HRT use was associated with higher CRP but, interestingly, similar 
IL-6 levels in those women not taking HRT [309]. Moreover, transdermal delivery of 
oestradiol appears not to be associated with elevation of CRP [294] [306] [296] which 
therefore may represent a “first pass” effect on hepatic CRP synthesis [302]. Since 
elevated CRP levels in men and women are independently linked to risk for CHD and 
stroke [310], the HRT-induced CRP rise has been put forward as a potential pathway 
explaining the results of HERS and WHI [234] [241]. It should be acknowledged, 
however, that even though vascular literature suggests several mechanisms whereby CRP 
may be directly atherogenic [310], it is not yet known whether the HRT-induced CRP rise 
leads directly or indirectly to a biologically adverse outcome.
Our data demonstrate a lack of significant rise in CRP in those assigned active therapy 
compared to the placebo group (p=0.62 crude, p=0.96 adjusted difference). Although 
power may be an issue here, studies in similar size to the present one, but employing 
CEE- or 2mg oestradiol-based preparations, have demonstrated significant, near two-fold 
elevations in CRP [301] [311]. A lack of CRP rise in the present study concurs with 
results from two other studies in non-diabetic women that used lower oestradiol doses 
(Img) [301] [312]. Moreover, HRT combining oral norethisterone with transdermal 
oestradiol may lower CRP [308]. Any tendency to an oestradiol-induced CRP elevation 
in the present study may have been attenuated by the oral norethisterone. The reduction 
in IL-6 concentration is of interest as androgens exhibit anti-inflammatory effects in 
several tissues [313]. Because of the variability of circulating inflammatory markers and 
the wide confidence interval in the result reported in this and studies of similar size [314] 
[315], larger studies using low dose HRT preparations are now urgently required to 
confirm our findings. In this respect, a potentially lower CHD risk with lower doses of
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HRT has recently been suggested by Ferrera et al [304] in their analysis of data from the 
Northern California Kaiser Permanente Diabetes Registry.
That triglyceride did not rise in this study is also relevant to CHD risk. Oral oestrogens, 
particularly CEE-based preparations, significantly increase circulating triglyceride 
concentrations by increasing hepatic synthesis of triglyceride-rich particles [305]. 
Increases in triglyceride concentration may enhance plaque instability by affecting 
platelet and endothelial function, as well as altering coagulation and vascular 
inflammation [316] [317]. Triglyceride concentration is independently linked to CHD 
risk, particularly in women [318]. Indeed, the HERS investigators speculated that the 
10% rise in triglyceride concentration in their study may have contributed to the early 
increase in CHD events despite the positive changes in other lipid parameters [241]. In 
general, increase in triglyceride concentration is less pronounced with oral oestradiol- 
containingHRT’s compared to CEE-based HRT’s and absent with transdermal delivery
[305]. Moreover, androgens decrease triglyceride concentration [305] [307], thereby 
opposing any tendency for an oestradiol-mediated increase.
Consistent with the reduction in factor VII coagulation activity (by 17%) with active 
treatment in this study, similat reductions have been reported with FIRT’s combining 
transdermal oestradiol with either oral MPA (10 mg) [319] or oral Img norethisterone
[306]. By contrast, oral 2mg oestradiol or 0.625mg CEE alone increase factor VII 
activity, whereas transdermal oestradiol has a negligible effect [243] [294] [306]. These 
data strongly suggest that oral progestogens reduce factor VII coagulation activity. The 
reduction in factor VII herein therefore indicates an overall hormonal balance favouring a 
dominant norethisterone action. Although elevated factor VII coagulation activity has 
been associated with an increased risk of coronary thrombosis in one study of men [41].
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Similar data in women are lacking. The relevance of HRT-mediated changes in factor 
VII levels therefore requires clarification.
A further potential benefit noted in our study was a reduction in fasting glucose 
concentration. Wliether this reflects an improvement in insulin action must be viewed 
with a degree of caution since we did not directly measure insulin action using clamp 
techniques, and many women were taking insulin therapy. Future studies should 
measures insulin action directly. Nevertheless, although HbAjc was not significantly 
altered, an improvement in insulin sensitivity or reduced hepatic glucose production 
accords with findings of two previous randomised placebo controlled trials in women 
with diabetes with unopposed oral 2mg 17|3-oestradiol alone [282] [266]. The recent 
report of a significant reduction in the incidence of diabetes (by 35%) in women with 
coronary disease assigned to active treatment in TIERS study as compared to those given 
placebo [320] suggests that conventional HRT may lessen risk of diabetes. Wlrether low 
dose HRT containing oestradiol and norethisterone has the same (or even larger) effect 
deserves further study.
The observed reduction in tPA-antigen (which largely measures circulating t-PA-PAl 
complexes) is in keeping with a reduction in PAI-1, which was not directly measured. 
PAI-1 has also been shown to fall in oral HRT studies [294] [321] [322]. Alternatively, 
the fall in t-PA may reflect reduced endothelial disturbance (i.e. t-PA release). 
Interestingly, elevated tPA-Ag (but not PAI-1) levels independently predicted CHD event 
rate in a recent meta-analysis of prospective studies in general populations [294].
There are several notable strengths of this study. Firstly, it is one of the very few 
randomised double-blind placebo-controlled trials of HRT in diabetic women, a group at
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elevated baseline risk of CHD and at potentially elevated CHD risk with conventional 
HRT therapy [303]. Secondly, the novel low dose preparation was very well tolerated 
and the side-effect profile was excellent, helping maintain investigator blinding. Thirdly, 
we tracked adherence to study medication by measuring oestradiol and gonadotrophin 
concentrations. Finally, we assessed a number of key pathways for CHD risk 
simultaneously, an approach that facilitated a more comprehensive assessment of the 
overall balance of metabolic, haemostatic and inflammatory effects of the low dose FIRT 
used. A limitation of our study is the modest number of patients recruited. Nevertheless, 
statistically significant changes detected in several key parameters indicate sufficient 
power to detect meaningful changes in pathways of interest; moreover, the results have 
biological plausibility. Our data therefore provide a strong basis for future studies 
examining the clinical safety of low dose HRT containing oestradiol and norethisterone 
in preference to conventional HRT containing CEE and MPA, supporting an emerging 
consensus that lower doses may be the safer option for many women [304] [318].
In conclusion, our study shows that low dose HRT containing Img oestradiol and 0.5mg 
norethisterone generates a vastly different portfolio of metabolic and haemostatic action 
compared to that observed with use of conventional higher dose HRT. Specifically, 
triglyceride, factor IX, APC resistance and CRP levels were statistically similar, whereas 
IL-6 and factor VII levels were significantly reduced and LDL-cholesterol lowering was 
retained. On the basis of our data, we suggest that a preparation containing low dose 
oestradiol combined with norethisterone may be more suitable for women who require 
HRT for menopausal symptom relief or bone protection but who are at higher risk of 
CHD, such as those with type 2 diabetes. However, before definitive recommendations 
ai’e made, such novel formulations should be assessed in a large randomised controlled 
trial powered for cardiovascular endpoints.
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CHAPTER 5
EFFECTS ON BONE MINERAL DENSITY
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5.1 Introduction
Hormone replacement therapy (HRT) is routinely used to treat menopausal symptoms 
and to prevent osteoporosis. Until recently, it was also commonly perceived that HRT 
might protect against coronary heart disease (CHD). However, recent data from two 
large prospective studies using 0.625 mg conjugated equine oestrogens (CEE) combined 
with medroxyprogesterone acetate (MPA) have demonstrated increased CHD risk with 
active therapy in largely healthy postmenopausal women [241] or those with prevalent 
CHD [234]. These findings have resulted in the abandonment of the recommendation of 
HRT for cardioprotection. Women with type 2 diabetes have a markedly elevated 
baseline risk for CHD. A recent report from a prospective observational study [303] 
suggested that HRT use leads to a significantly increased risk of death from all causes 
and ischaemic heart disease among women with diabetes. Current users of HRT with 
diabetes had a near ten-fold increased risk of myocardial infarction (9.2, 95% Cl, 2.0 to 
41.4) compared with never users with diabetes.
There is an emerging consensus that lower doses may be the safer option for many 
women [304] [323]. Moreover, experts in the field are beginning to recommend use of 
lower dose oral preparations, perhaps containing oestradiol rather than CEE and 
progestogens other than MPA [324].
Postmenopausal women with diabetes are at markedly elevated CHD risk and recent data 
suggests this group may also be at significantly elevated risk of hip fractures [209]. 
Strategies to prevent osteoporosis may be especially warranted in women with diabetes.
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Such women may therefore receive particular benefit from HRT but little data exists on 
the effects of low dose preparations on bone mineral density (BMD). Here, we examined 
if six months treatment with a low dose continuous combined HRT containing Img 
oestradiol and 0.5 mg norethisterone significantly increases BMD relative to placebo and 
reduces serum bone alkaline phosphatase (BAP) in post menopausal women with type 2 
diabetes.
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5.2 Methods
5.2.1 Subjects recruited
50 women aged under 70 years of age were recruited from general diabetes clinics in 
Glasgow Hospitals. Women randomised were clinically and biochemically 
postmenopausal i.e. with at least one year since last menses and a follicle stimulating 
hormone (FSH) concentration of greater than 20 IU/1. A normal pelvic examination and 
mammogram within the year prior to inclusion in the trial was also required. Women 
were included with a widespread of glycaemic control but all had an HbAlc of < 10  and 
no evidence of significant hypertriglyceridaemia, hypertension, and renal or liver disease. 
In addition, none had cardiovascular, cerebrovascular, or peripheral vascular disease. 
Subjects with either a personal history of - or first-degree relative with - breast cancer 
were excluded.
5.2.2 Study Visits.
Women eligible at screening were randomised to prescription of either active medication 
or identical placebo daily for six months. Compliance was assessed by oestradiol and 
gonadotrophin concentration measures at the final visit. A requirement of oestradiol to 
rise by more thanlO pmol/1 and FSH to decline by more than 5 U/L was pre-defined. The 
participating hospitals’ local reseai'ch ethical committees granted ethical approval. 
Existing medications for glycaemic control, blood pressure or lipid lowering (detailed in 
Table 4.1 ) were not altered throughout the course of the study.
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The BMD in the lumbar spine (L2-L4) and hip were measured using dual-energy x-ray 
absorptiometry (Lunar DPX+). The densitometer was calibrated daily using the local 
Lunar spine phantom. Daily spine phantom quality control was within 1% of the 
reference value. The coefficients of variation for the anatomic phantoms during the 
baseline scans were 0.46% for the spine and 0.58% for the hip. The software program for 
the DXA scan had a comparison feature that permitted identical regions of interest to be 
used on the repeat scans. For the hip these regions of interest were total hip, femoral 
neck. Ward’s triangle, femoral shaft and trochanter. During the course of the trial the in 
vivo coefficients of variation were 1.2% or less for measures of spine and hip.
The same patients also underwent a series of metabolic tests, the results of which have 
already been presented elsewhere [325].
5.2.3 Statistical analysis
Baseline data are presented as mean and SD. Mean differences in changes from baseline 
between the active and placebo groups were compared using the unpaired t-test: the 95% 
confidence interval for change in active group data relative to change in control group 
data are presented. Adjustment for baseline concentrations was made by linear regression.
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5.3 Results
5.3.1 Subjects recruited
Of the 50 women randomised, five did not complete the study due to either relocating or 
personal reasons. Of the women completing the study, 22 were in the active group and of 
these 19 adhered to study medications as evidenced by an increase in oestradiol (>10 
pmol/1) and fall in FSH (>15 U/L). There were no serious adverse events. Three women 
(16%) reported breast tenderness and breakthrough bleeding on active treatment but none 
on placebo.
Table 4.1 demonstrates the baseline characteristics of women completing the study. The 
groups were similar in age, BMI, blood pressure and years since menopause. All 
categories of diabetes therapy were represented and similar percentages were taking anti­
hypertensive or lipid-lowering agents. A significant reduction in gonadotrophin 
concentrations and an elevation in oestradiol (both p<0.001) was observed in women 
randomised to active therapy (data not shown).
5.3.2 Bone Mineral Density (BMD) and Bone Alkaline Phosphatase (BAP) changes.
Table 5.1 shows the BMD changes in both groups. Significant changes were seen at all 
sites - total hip. Ward’s triangle, femoral shaft and trochanter - except, as anticipated, the 
neck of femur. In addition, serum bone alkaline phosphatase decreased in the active 
group by 23% but marginally increased in the placebo group such that relative change
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was highly significant (p<0.001 ). The changes in BMD remained significant after 
adjustment for baseline BMD, BMI, years post-menopausal and serum BAP.
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Table 5.1
Baseline and changes over six months in bone mineral density (BMD) and serum bone 
alkaline phosphatase (BAP) in women randomised to HRT and placebo.
Active
Baseline
Mean
Change
(%)
Placebo
Baseline
Mean
Change
(%)
Difference P ="p
BMD
L2-L4 1.213 +0.023 1.083 -0.021 0.073 0.004 0.006
Neck 0.905 +0.001 0.825 -0.001 0.003 [- 0.83 0.63
Wards 0.763 +0.003 0.710 -0.028 0.031 0.063 0.028
Trochanter 0.825 +0.015 0.798 -0.038 0.053 0.020 0.010
Shaft 1.168 +0.021 1.114 -0.014 0.035 0.028 0.045
Total
1.003
(0.041)
+0.012
(1.19)
0.945
(0.032)
-0.018 0.030 
[0.004 to
0.027 0.040
Serum BAP
20.54
(1.40)
-4.79
(23.3)
21.59
(1.55)
1.31 -6.10 [-2.94 
to -9.26]
<0.001 <0.001
p = p-value adjusted for baseline BMD (or BAP), years post-menopausal, and baseline 
BMI.
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5.4 Discussion
We demonstrate for the first time that low dose continuous combined HRT benefits BMD 
in a gi'oup of postmenopausal women with diabetes, a group with markedly elevated 
CHD risk. Interestingly, recent data indicate that doses of CEEs-MPA lower than 0.625 
mg/d effectively increase BMD in early postmenopausal women [326]. The relevance of 
our data on an HRT containing low dose oestradiol (as opposed to conjugated oestrogens) 
and northisterone (as opposed to MPA) is that such an HRT is more likely to avoid many 
of the adverse metabolic effects and associated elevated CHD risk seen with conventional 
higher dose HRT and thus the excess risk for CHD [241] [234]. Indeed, we have already 
reported statistically similar triglyceride, factor IX, APC resistance and CRP levels with 
this preparation in these patients, whereas IL-6 and factor VII levels were significantly 
reduced and LDL-cholesterol lowering was retained [325]. This profile of effects differs 
markedly from that obtained by CEE-MPA based HRT which increases triglyceride, CRP 
and factor VII. Therefore, we have suggested that the preparation used herein is likely to 
avoid the elevated CHD risk seen with more conventional preparations as used in HERS 
and WHI.
It is important to note that the extent of improvement in BMD with 6 months treatment of 
the novel low dose combined oestradiol/norethisterone preparation was in the range of 1- 
2%. This improvement is at least equivalent, perhaps even superior, to effects seen with 
lower dose CEE, as reported in a recent multi centre US trial conducted in early post­
menopausal women [326].
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There are several notable strengths of this study. Firstly, it is one of the very few 
randomised double-blind placebo-controlled trials of HRT in diabetic women, a group at 
elevated baseline risk of CHD and at potentially elevated CHD risk with conventional 
HRT therapy [234]. Secondly, the novel low dose preparation was very well tolerated 
and the side-effect profile was excellent, helping maintain investigator blinding. In terms 
of clinical benefit, fewer side effects will only serve to enhance compliance such that 
long-term therapy, critical for osteoporosis prevention, is more sustainable. Finally, we 
tracked adherence to study medication by measuring oestradiol and gonadotrophin 
concentrations.
In conclusion, we have shown for the first time that a low dose HRT containing 1 mg 
oestradiol and 0.5 mg norethisterone improves BMD in women with type 2 diabetes and 
does so by approximately the same magnitude of low dose CEE-based preparations.
Since women with type 2 diabetes are at elevated risk for CHD and conventional 
CEE/MPA-based HRT’s increase such risk, there is an increasing need to consider lower 
dose preparations containing differing oestrogens and progestogens. Accordingly, our 
data provide important reassurance that lower dose HRT can be confidently prescribed 
for protection against bone loss in women with type 2 diabetes.
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CHAPTER 6
LIVER EFFECTS
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6.1 Introduction
Insulin resistance plays a central role in type 2 DM and glucose intolerance. There is also 
a strong association between type 2 DM and liver disease. Approximately 75% of 
patients with diabetes may have non-alcoholic fatty liver (NAFL) [327]. Additionally, 
the role of the liver in the pathogenesis of type 2 diabetes is increasingly considered.
Both directly determined liver fat content [328] and circulating levels of alanine 
aminotransferase (ALT) [329] [330] [331] and gamma-glutamyl y transferase (GOT),
[332] [333] [334] which reflect liver fat content, have been shown by ourselves and 
others to be associated with diabetes risk, independently of alcohol consumption, in 
prospective studies.
The Women’s Health Initiative (WHI) [234] randomized 15,000 women to receive either 
0.625mg of conjugated equine oestrogens and 2.5mg of medroxyprogesterone acetate or 
placebo each day. The study was halted after an average of 5.6 years because of adverse 
cardiovascular events in the intervention arm. Evaluation of the data after the end of the 
study did, however, reveal that women randomised to active therapy had a lower 
incidence of self-reported diabetes relative to placebo recipients, with a hazard ratio of 
0.79 (nominal 95% Cl 0.67-0.93). This hazard ratio was unaffected by adjustment for 
changes in body mass index or waist circumference.
In view of the above observations, data indicating HRT users have a better profile of liver 
function tests are of interest. For example, in the National Health and Nutrition 
Evaluation Survey (NHANES) III data [115] on liver enzymes in -12,000 subjects 
representative of the U.S. population, lower levels of NAFLD were seen in 
postmenopausal women taking hormone replacement therapy (HRT). Whilst the latter 
data are observational and maybe confounded by unmeasured factors, a beneficial effect
124
of HRT to lessen liver fat accumulation may be speculated. Randomized controlled data 
to directly test this speculation are absent. We had an excellent opportunity to examine 
changes in liver function tests in a randomized double-blind placebo-controlled trial of a 
low dose continuous combined HRT (Img 17|3-oestradiol and 0.5mg norethisterone 
acetate) in postmenopausal women with type 2 diabetes. We have already shown this 
preparation to offer a beneficial metabolic profile inclusive of lower lipids, glucose and 
cytokine concentrations [325]. Thus, we tested the hypothesis that liver function test 
concentrations would be improved by HRT relative to placebo effects in women with 
type 2 diabetes.
125
6.2 Methods
6.2.1 Subjects Recruited
The subject recruitment has been described in detail previously. [325] Briefly, 50 women 
with type 2 diabetes aged under 70 years of age who were clinically and biochemically 
postmenopausal were recruited. A normal pelvic examination and mammogram within 
the yeai' prior to inclusion in the trial was also required. Exclusion criteria included poor 
glycaemic control, severe hypertriglyceridaemia (>10 namol/1), moderate to severe 
hypertension (systolic >160 mmHg, diastolic >110 mmHg), renal impairment (serum 
creatinine greater than twice the upper limit of normal range), liver disease (serum 
transaminases and bilirubin greater than twice the upper limit of normal range). 
Established cardiovascular, cerebrovascular, or peripheral vascular disease also excluded 
selection. Subjects with either a personal history of, or first-degree relative with, breast 
cancer were excluded.
Women eligible at screening were randomised to prescription of either active medication 
(Img oestradiol plus 0.5mg norethisterone) or identical placebo daily for six months. 
Randomisation was effected in blocks of four using computer-generated numbers. 
Compliance was assessed by returned medication packs at the final visit and by oestradiol 
and gonadotrophin concentration measures at the final visit. A requirement of oestradiol 
to rise by more than lOpmol/1 and FSH to decline by more than 5 U/L was pre-defined.
The participating hospitals’ local research ethical committees granted approval. All 
subjects gave written informed consent to a single investigator (JM). As far as possible.
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existing medications for glycaemic control, blood pressure or lipid lowering (Table 4.1) 
were not altered throughout the course of the study.
6.2.2 Study visits
Women attended the Diabetes Centre, Glasgow Royal Infirmary, Glasgow at baseline and 
6 months, having fasted for 10 hours and avoided heavy exercise, alcohol and caffeine in 
the preceding 24 hours. Subjects rested prone for 15 minutes prior to blood pressure 
recordings being taken in triplicate (mean recorded). The women also had anthropometric
2 2(cm). From these body mass index (BMI) was calculated as weight/(height) in kg/m ,
measurements to include height (cm), weight (kg), and waist and hip circumferences 
 
as well as waist to hip ratio (WHR).
6.2.3 Laboratory methods
The reproductive hormones: oestradiol, luteinising (LH), follicle stimulating hormone 
(FSH), testosterone and sex hormone binding globulin (SHBG) were measured using 
semi-automated Tmmulite’ technology (DPC, Los Angeles, USA). ALT and AST were 
determined on fresh samples using standard reagents by reaction rate assay based on the 
conversion of NADH to NAD. All AST, ALT, GGT and alkaline phosphatase (ALP) 
analyses were conducted in the same laboratory with adherence to external quality 
control. The between batch CV for their determination was <5%.
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6.2.4 Statistical analysis
Baseline ALT, AST and GGT were skewed and geometric means and SD are presented. 
Changes in ATL, AST and ALP were normally distributed and thus difference in change 
from baseline between the two treatment groups was compared using the unpaired t-test: 
the 95% confidence intervals for change in active group data relative to change in control 
group data are presented. Adjustment for baseline concentrations was made by linear 
regression. Changes in unadjusted GGT in active and placebo groups were skewed so we 
compared changes using logged values.
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6.3 Results
6.3.1 Subjects Recruited
58 women were recruited from a general diabetic clinic and screened as potential recruits 
into the study. Of these, 50 were randomised. The eight women not entered had 
unacceptably high HbAlc (n=3), abnormal LFT’s (n-2), abnormal mammogram (n=2) or 
abnormal pelvic examination (n=l), the latter two categories necessitating further 
investigations. Five women did not complete the study due to either moving home or 
other personal reasons. Forty-five women therefore completed the study and of the 22 in 
the active group, 19 demonstrated compliance as evidence by an increase in oestradiol 
and fall in FSH. None of the women in either group suffered any serious adverse effects. 
Breast tenderness and breakthrough bleeding were reported in three women in the active 
group but none in the placebo arm.
Table 4.1 demonstrates the baseline characteristics of women completing the study. The 
groups were similar in age, BMI, blood pressure and years since menopause. All 
categories of diabetes therapy were represented and similar percentages were taking anti­
hypertensive or lipid-lowering agents. A significant reduction in gonadotrophin 
concentrations and an elevation in oestradiol (both p<0.001) was observed in women 
randomised to active therapy (data not shown).
6.3.2 Changes in Liver Function Tests
Table 6.1 demonstrates baseline and 6 month alterations in serum ALT, AST and ALP 
concentrations in placebo and active gi'oups. It was of note that all three analytes
129
declined in concentration in the active group relative to placebo. The mean changes for 
all three analytes were pronounced. Figure 2 demonstrates significant reduction in serum 
GGT levels in the active relative to placebo recipients. Baseline levels were not 
significantly different in women randomized to active or placebo groups. In order to test 
for any potential confounding by baseline levels, we further compared changes in 
parameters with adjustment for baseline levels and noted that significant active-placebo 
differences were retained (Table 4.1).
When we examined relationship between reductions in relation to baseline concentrations 
(Table 6.2, Figure 3), we noted very strong correlations in the active group for all four 
analytes whereas only AST was borderline significant in the placebo group. Similarly, 
the magnitude of reduction in AST, ALT and GGT were highly correlated in the active 
group (majority p<0.01) whereas no such significant associations were noted in the 
placebo group.
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Table 6.1
Baseline and changes over six months in liver function tests in women randomised to 
HRT and placebo.
Active
Baseline
Mean
change
Placebo
Baseline
Mean
change
Delta for active 
vs. placebo
p value 
delta
''T value 
delta
ALT 28.7 (1.9) -13.1(16.8) 20.7 (1.6) 1.27 (5.6) -14 (-23 to -6) 0.002 0.004
AST 22.1 (1.5) -5.8 (7.3) 18.7(1.5) 3.4 (7.0) -9.2 (-14 to -5) <0.001 <0.001
ALK
Phos
217.6 (40) -54.21 (31) 210.9 (51) 6.6 (29) -61 (-80 to -42) <0.001 <0.001
■^•p value=p value delta adjusted for baseline
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Table 6.2.
Correlation of change with baseline liver function tests concentrations in active and 
placebo group.
Active Placebo
ALT change vs baseline ALT R=0.93, p<0.001 R=0.17,p=0.44
AST change vs baseline AST R=0.90, p<0.001 r=0.44, p=0.04
ALP change vs baseline ALP R=0.68, p=0.001 R=0.11,p=0.63
GGT change vs baseline GGT R=0.87, p<0.001 R=-0.30, p=0.17
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Figure 2
Reduction in serum GGT levels in the active relative to placebo participants.
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Figure 3.
Association of change with baseline ALT levels in women randomized to placebo or 
active therapy.
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6.4 Discussion
In a randomized placebo controlled study we have demonstrated that an HRT containing 
Img 17p“ oestradiol and 0.5mg norethisterone can significantly lessen circulating 
concentrations of routinely measured liver function tests (ALT, AST, GGT and ALK 
Phos) in women with type 2 diabetes. Such observations are relevant for a number of 
reasons. Most importantly, excess liver fat is a common occurrence in obesity and in 
patients with type 2 diabetes. Indeed, the average levels of ALT and AST in the women 
in this study were much higher than recently suggested normal levels for women from a 
recent large population survey. A subset of patients with NAFL, previously thought to be 
a benign non-progressive condition, can develop advanced fibrosis, cirrhosis and 
hepatocellular carcinoma [335]. The presence of obesity and/or type 2 DM are the 
strongest predictors of fibrosis [336]. Secondly, excess liver fat, even within the 
subclinical range as demonstrated by ALT or GGT levels, signal elevated risk for type 2 
diabetes and perhaps indicate a role for liver fat accumulation in the pathogenesis of type 
2 diabetes. Finally, a recent large multi centre study suggested HRT may reduce risk for 
type 2 diabetes but mechanisms were not examined [234]. Our results suggest an HRT 
mediated reduction in liver fat could account for some of the above observations.
A possible mechanism by which HRT may lessen liver function tests is by a reduction in 
liver fat. Elevations in GGT, ALP, AST and in particular ALT have been shown to 
correlate with excess liver fat and insulin resistance and ALT and GGT are now well 
described as predictors of type 2 diabetes [329] [330] [331] [332] [333] [334]. Elevated 
ALT is now used, together with other metabolic markers, as a risk factor signaling excess 
liver fat and the need to further investigate NAFL. Thus the parallel reductions in ALT, 
AST and GGT in the active group would be consistent with a reduction in liver 
fat.[335][336] The significant reduction in fasting glucose reported previously in this
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study [325] would be in keeping with lower fat accumulation since hepatic fat 
accumulation is linked to increased hepatic gluconeogenesis [337]. Although part of the 
reduction in ALP may come from effects on bone metabolism, the relative extent of 
change in the active group in this parameter (-25%) would suggest an effect on liver 
generated ALP is also likely. Previous studies have suggested that elevations in ALP 
may also be linked to NAFL [338].
We cannot determine directly by our study design whether the oestradiol or 
norethisterone component of the HRT was responsible for the beneficial effect on liver 
tests. Androgenic progestogens, such as norethisterone lessen circulation concentrations 
of a range of factors produced by the liver (e.g. triglyceride. Factor VII etc), whereas 
oestrogens do the reverse [244]. One could speculate that androgenic progestogens up- 
regulate hepatic beta-oxidation, leading in turn to lower hepatic fat accumulation. 
Triglyceride (albeit not significantly) and factor VII concentrations were lowered in this 
study with active therapy [325] suggesting a dominance of the androgenic effect with the 
HRT used. Wliilst direct evidence for our supposition is lacking, other data indicate oral 
oestrogens may increase triglyceride concentrations by ‘decreasing’ hepatic beta- 
oxidation [339]. It is also relevant that previous studies have shown a beneficial effect of 
unopposed oestradiol on liver insulin sensitivity [266] [282], but effects on liver function 
tests or liver fat were not measured. Finally, it is notable that PPAR gamma agonists may 
exert their insulin sensitizing effects in part by reducing liver fat content [340].
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CHAPTER 7
DISCUSSION
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7,1 Summary of study.
The purpose of this study was to examine the effects of a low dose continuous combined 
HRT preparation on insulin sensitivity, lipid profile, clotting factors and markers of 
endothelial function and inflammation in postmenopausal women with type 2 DM. This 
study showed a significant fall in fasting insulin (p=0.043) and C-peptide p=0.003). 
Fasting glucose (p=0.026) also declined significantly, but there were no significant 
effects on HBAlc or BMI which did not fall. The study would suggest that in terms of 
glucose metabolism and control of diabetes a low dose combined continuous HRT would 
not lead to any determination in control, but may be as our trial was not powered to detect 
such a change.
The changes in lipid profiles in our patients were as expected from previous work with 
total and LDL-cholesterol both showing significant falls (p= 0.020 and 0.018 
respectively). The HDL-cholesterol did not unfortunately rise, but due to the fall in LDL- 
cholesterol the ratio of total: HDL-cholesterol did fall by a significant amount (p-0.05) 
Triglyceride concentrations were also not significantly altered. Haemostatic and 
inflammatory variables showed a significant fall in Interleukin-6 concentration. Factor 
VII and tissue plasminogen activator antigen concentrations, (p -0 .015,<0.001 and 0.005 
respectively) but CRP, factor IX and APC resistance did not alter significantly.
It would seem that HRT containing Img oestradiol and 0.5mg norethisterone may avoid 
the adverse metabolic and haemostatic effects potentially implicated in the elevated CHD 
and stroke risk. Specifically, triglyceride, factor IX, APC resistance and CRP levels were 
statistically similar, whereas IL-6 and factor VII levels were significantly reduced and 
LDL-cholesterol lowering was retained. The above can only be surmised as our trial did
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not include enough women or for a long enough time period for us to make any 
comments on CHD and stroke risk and only examined surrogate markers.
7.2 Studies of HRT in Women with DM
A recently reported study of the effect of a continuous combined HRT, Kliofem (2mg 
17(3-oestradiol, Img norethisterone acetate) as used in our pilot study, recruited 150 
postmenopausal women with either type 2(94) or type 1 DM(56) into a randomised 
controlled study over a 1 year treatment period [341]. Seventy patients failed to complete 
the study and may affect any results that were found. This HRT was found to have 
neutral effects total and LDL cholesterol and triglycerides in either type 1 or type 2 DM.
A difference was found in the effect of HRT on HDL-cholesterol in the 2 treatment 
groups. There was a significant decrease (p<0.001) in patients with type 1 diabetes but 
no decrease in those with type 2 diabetes. The mean difference of the change in HDL 
cholesterol between the 2 types of diabetes being 0.12 (p=0.008). The researchers offered 
no explanation for this difference but thought it warranted further study [341]. This result 
must be assessed on the background of the differences in lipid abnormalities in patients 
with type 1 and type 2 DM i.e. patients with type 2 DM typically have low HDL 
cholesterol levels but patients with type 1 DM have normal or elevated HDL cholesterol. 
This elevated HDL cholesterol does not confer a cardiovascular benefit possibly due to 
the HDL cholesterol subfractions which are elevated [341].
One observational study of Danish Nurses which recently reported could not find any 
significant association between current or ever use of HRT and ischaemic heart disease, 
MI or death from all causes [303]. They found that the effect was modified by the 
presence of DM. Women with DM who were current users of HRT had significantly
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increased risk of ischaemic heart disease (HR 4.2, 95% Cl 1.4-12.5), MI (9.2, 2.0-41.5) 
and death from all causes (3.2, 1.4-7.5) compared with women with diabetes who had 
never used HRT [303]. The HRT used could be, oestrogen alone or oestrogen plus 
progestogen, but in all cases the doses used were higher than used in our study [303].
7.3 Randomised Controlled Studies of HRT
The first primary and secondaiy cardiovascular prevention trials in women without type 2 
DM reported during this study and as discussed earlier no benefits from HRT have been 
seen. The first to report was the Heart and Estrogen/Progestin Replacement Study 
(HERS) [241] which was designed to assess the efficacy of HRT for secondary 
prevention of cardiovascular endpoints. This trial reported that a fixed combination of 
0.625mg per day of CEE and 2.5mg of MPA had no effect on fatal and nonfatal cardiac 
events compared to placebo. This study of 2763 American women with a mean age of 67 
years followed up for an average of 4.1 years. After 4 years of follow-up there were 179 
CITD events in the HRT group and 182 in the placebo group with 57 events in the HRT 
group and 38 in the placebo group in year 1 (relative hazard (RH) 1.5). In the first 4
months of the trial there was a RH of 2.3. In years 4 and 5 in contrast there were 40
events in the HRT group and 53 in the placebo group (RH 0.75).
I The average duration of follow up was 7 months less than originally planned as
enrollment of a large percentage of participants took place within the final 6 months of 
the 18 month recruitment period. A higher than expected crossover rate between the 
groups was also encountered in the HERS trial. There was a 1.7% per year cross over 
rate from placebo to HRT (1% per year was expected) and an 18% crossover from HRT 
to placebo in the first year (5% was expected). Also the event rate in both groups was
) much lower than expected, being 3.3% per year rather than 5% which was expected. It
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was predicted that the event rate in the placebo group would be 24% when the actual rate 
was 13%. The explanation given for this lower event rate was that more women than 
ever are treated with statins, aspirin, (3-blockers and angiotensin-converting enzyme 
inhibitors all of which decrease events in patients with CHD [342],
The HERS investigators reported on the observation that changes in lipid levels with 
HRT are not predictive of cai'diovascular outcomes in women with heart disease [343]. It 
would seem that baseline levels of HDL-c and on treatment levels of LDL-c are 
significantly associated with cardiovascular events, but reduction in LDL-c had only a 
modest association with events and increases in HDL-c and triglyceride levels had no 
association with cardiovascular risk. The reasons for this observation may be that any 
beneficial effects in LDL-c and HDL-c are opposed by a rise in TG levels.
Soon after the HERS trial had reported the lai'ge primary prevention trial which was 
designed to define the risks and benefits of strategies that could potentially reduce the 
incidence of heart disease, breast and colorectal cancer and fractures in postmenopausal 
women was prematurely stopped. This was due to the preset threshold for increased 
numbers of breast cancer being breached. This trial was one component of the Women’s 
Health Initiative (WHI) [234] the first randomized primary prevention trial of 
postmenopausal hormones for CHD. Between 1993 and 1998 the WHI enrolled 161,809 
postmenopausal women in the age range 50-79 into a set of clinical trials at 40 clinical 
centres in USA. The primary outcome for the HRT trials component was CHD. Hip 
fractures were a secondary outcome. Invasive breast cancer was designated a primary 
adverse outcome. Additional clinical outcomes chosen as secondary outcomes that could 
be affected by HRT included other cai'diovascular disease, endometrial, colorectal and 
other cancers and other fractures. 16,608 women with intact uterus were recruited to the 
oestrogen and progestin component of the trial. They were randomized to receive either
141
placebo or a continuous combined combination of 0.625mg CEE and 2.5mg MPA (as in 
the HERS study). The trial was stopped 3 years early based on health risks that exceeded 
health benefits after an average follow-up of 5.2 years. A parallel trial of oestrogen alone 
in women who have had a hysterectomy is continuing to its planned date of completion in 
2005 when average follow-up will be 8.5 years. The trial was stopped because women in 
the active treatment group had an increased risk of breast cancer (hazard ratio (HR) 1.26, 
95% Cl 1.00-1.59) which was above a predetermined level. Several other results were 
also causing concern including increased CHD (HRl .29, 95% Cl 1.02-1.63), stroke (HR 
1.41, 95% Cl 1.07-1.85) and pulmonary embolism (HR2.13, 95% Cl 1.39-3.25). 
Beneficial results included decreases in colorectal cancer (HR 0.63, 95% Cl 0.43-0.92) 
and hip fracture (HR 0.66, 95% Cl 0.45-0.98). Numbers of deaths in the active and 
placebo group were similar. Only 3.5% were lost to follow up and during the study 
compliance reached 48% in the active group and 62% in the placebo group. This 
exceeded that expected and may influence the intention to treat figures which have yet to 
be reported.
Most adverse events began appearing within the first 2 years of the trial but increased 
cancer risk did not occur until after year 3. Results in subgroup analyses are consistent 
suggesting there is not any particular group of patients who would benefit more from the 
HRT studied. The authors concluded that results from WHI indicated that the combined 
HRT preparation of 0.625mg CEE and 2.5mg MPA should not be initiated or continued 
for the primary prevention of CHD.
The findings of WHI as regards preventing CHD concurs with the HERS and HERS II 
findings in women with clinically apparent CHD. The findings in WHI for stroke are 
also consistent with those in PIERS although somewhat more extreme. The findings as 
regards venous thromboembolism are consistent in both WHI and HERS trials. Although
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it was the prevalence of breast cancer that crossed a designated safety boundary and lead 
to the early termination of WHI the breast cancer results are not unexpected from earlier 
observational data [228] [229]. The 26% excess risk is also consistent with a non­
significant 27% increase found in the HERS II trial. The reduction in colorectal cancer in 
the hormone group is consistent with observational studies which have suggested fairly 
consistently that users of HRT may be at lower risk of colorectal cancer [344].
The results of the HERS and WHI trials lead to much discussion. The validity of the 
results was questioned. In particular the age of the women in the trial was seen as a 
possible reason for the lack of benefit. Animal studies had previously shown that when 
CEE was initiated at time of oophorectomy there was a 50-70% decrease in coronary 
plaque, but if CEE was started years later no benefit to plaque formation or stabilization 
was seen. [345] This may suggest that HRT has less effect on limiting the atherosclerotic 
process if plaques are already developed as may have occurred in WHI and in HERS 
trials. The average age of the women in the WHI (CEE+MPA) trial was 63, the sample 
including only 10% in the lowest cohort of 50-54 years and 20% between 54-59 years.
No information in either trial was given as to age at menopause of the subjects which 
may be important in defining cardiovascular status, which changes with age and more 
rapidly after menopause. [2] Similarly in the women randomized to HRT in WHI, 36% 
had hypertension, 49% were current or past smokers. It is possible therefore that 
although subjects were designated as healthy the process of atherosclerosis was likely to 
be active in these women. Supporters of HRT suggested that if loss of hormones permits 
rapid progression of atherosclerosis then early intervention with HRT perhaps in the 
peri menopausal period would be more effective. Prescribing of HRT to older women for 
cardioprotection until the time of the trial had become common clinical practice that the 
trials were designed to evaluate and as mentioned earlier, in the WHI (CEE+MPA) trial 
the women at greatest risk were found to be in the youngest cohort.
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The generalisability of the results from HERS and W tll were also questioned on the basis 
of the HRT preparation used. CEE is a mixture of steroids extracted from equine urine 
and is uncertain composition, but its main active ingredient is sodium oestrone sulphate. 
After menopause women lose oestradiol (major ovarian hormone) whereas the levels of 
oestrone (largely produced in peripheral tissues) remains unchanged. In this way it can 
be seen that CEE does not replace oestradiol. CEE and ostradiol by definition are both 
oestrogen as they can bind to and activate oestrogen receptors but the pharmacological 
properties are known to vary considerably and may have influenced the final outcomes of 
the trials. A Swedish study found a reduced risk of MI for oestradiol compared to oral 
oestriol or vaginal oestriol/dienoestrol. [346]
In vitro studies using human aortic smooth muscle cells (SMC) demonstrated that 
oestrogens present in CEE were significantly less potent compared with oestradiol in 
inhibiting mitogen induced SMC growth and mitogen activated protein kinase activity. 
Abnormal gi’owth of SMC plays a role in CHD and the lack of antiproliferative action 
with CEE could be partly responsible for the negative outcomes of HERS and WHI.
[347] In the Estrogens in the Prevention of Atherosclerosis (EPAT) study which was a 
primary prevention study where women were randomized to oestradiol or placebo after 
hysterectomy progression of intimai thickening was seen in repeat angiography after 3.2 
years of follow up. [348] These findings may provide evidence that use of differing 
oestrogens may have a differential effect on CHD effects of HRT. Much of the 
observational data that demonstrated a positive effect of HRT however was seen with 
CEE.
The use of MPA in both the HERS and WHI has also been blamed for the lack of CHD 
effect. In support of this idea in the PEPI trial CEE caused beneficial effects on LDL-C
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and HDL-C levels that were attenuated by MPA. [270]. The interpretation of this is that 
MPA may decrease the protective effects of oestrogen on the cardiovascular system. 
This observation is not supported by the observation that CEE and CEE+MPA were 
equipotent in inhibiting atherosclerosis in nonhuman primates and also in the WHI CEE 
alone study no protective effect on CHD was seen even though lipids were favourably 
changed. In the Nurses Health Study a similar risk reduction for CHD was seen among 
women taking CEE alone or CEE+ MPA. Also in the ARIC study reductions in intimai 
medial thickness were similar in women receiving oestrogen alone or oestrogen plus 
MPA. [281]
Examination of the results of HERS and WHI trials seemed to suggest that the effects of 
HRT changed over time in the study. Some reports were that HRT was only harmful at 
the initiation of treatment and could be beneficial by the end. The relative risk was seen 
to change over time in the HERS trial with RR in the first year of trial being 1.52 and the 
RR in years 4 to 5 being 0.75 however in no year did HRT users have a lower risk than 
non users and in the final year of the trial the RR had a very wide confidence interval 
crossing 0 of 0.50-1.13. These finding did lead to a unifying hypothesis of the effects of 
HRT on the cardiovascular system of “early harm and late benefit.”[349] This was based 
on 3 possible processes induced by HRT. These were
1. Early plaque erosion/rupture made worse by CEE+ MPA
2. Long term reduction in plaque formation by the beneficial effects of HRT on 
lipids
3. Relative antagonism of vasculoprotective effects of oestrogen by MPA.
If HRT is begun under conditions where vulnerable plaques have accumulated i.e. 
women years after the menopause as in the HERS and WHI trials the effects of plaque 
erosion and rupture will dominate initially -early harm- and it may take some years for
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the decreased plaque formation caused by the positive lipid effects to be seen-late benefit. 
There is a possible biological mechanism for this hypothesis in that oestrogens promote 
the production of matrix metalloproteinases (MMPs) which contribute to erosion and 
rupture of vulnerable preformed plaque (early harm) but which facilitate remodeling of 
stable plaque (late benefit).[349]
The aim of this hypothesis is to explain both the observational trial data and the 
controlled trial data. It would assert that if HRT is started at the time of menopause, as in 
the observational trials, when vulnerable coronary plaque is limited HRT should produce 
a decrease in CHD. At this time more of a benefit should be expected either from oral 
oestrogens (more of arise in HDL-c than transdermal oestrogens) [350] or transderm al 
oestrogens (less of a rise in inflammatory markers e.g. CRP) than oral oestrogen). [290] If 
instead HRT is commenced years after menopause as in WHI and HERS trials when 
vulnerable coronary plaque load is extensive there will be a sharp increase in CHD events 
within the year or two after therapy is begun largely reflecting inflammation induced 
and/or MMP induced plaque erosion and rupture. If HRT is continued there will be 
fewer events as time progresses with a net benefit after 5-6 years as seen in WHI and 
HERS. As the initial increase in CHD events is due to the release of prothrombotic and 
proinflammartory factors from the liver stimulated by oral oestrogens these problems 
could be lessened by the use of transdermal oestrogens at this stage. If some of the 
positive effects of oestrogen on the cardiovascular system are negated by progestogens 
especially MPA there should be greater benefits seen in women taking oestrogen alone or 
with more androgenic progestogens e.g. norethisterone which is consistent with some 
observational studies. [75] Also if the increased risk of breast cancer seen in HERS and 
WHI is due to constant exposure of the breast to circulating progestogen as has been 
suggested than this risk could be lessened if progestogens used were less likely to
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increase breast density i.e. norethisterone rather than MPA[349] or if the progestogen 
eould be given locally to the uterus e.g. by a progestogen impregnated uterine coil.
The most consistently adverse effect in both the HERS and the WHI studies, as well as 
others has been the increase in triglyceride levels. In the WHI there was a 6.9% rise in 
the treatment group compared to the placebo group levels [234]. This is consistent with 
the rise seen in the HERS study treatment group compared to the placebo group of 10% 
in the first year [241]. The rise in triglycerides may also result in an overestimate of the 
decrease in LDL-cholesterol based on the Friedwald equation for estimation of LDL- 
cholesterol levels as was carried out in both of the large trials. As we have discussed 
earlier elevated blood triglycerides are an important risk factor for both CHD and stroke 
especially among women [35]. The elevated triglycerides being associated with higher 
levels of small dense LDL-cholesterol which are particularly atherogenic. [37] They are 
also associated with lower HDL-cholesterol levels. The elevation in the triglycerides 
seen with CEE containing HRT is due to greater production of VLDL-cholesterol in the 
liver. This is not seen with oestradiol containing HRT preparations as in our own study. 
After correction for lipid levels in the HERS trial it can be seen that neither baseline nor 
on treatment triglycerides are related to CHD incidence. Clearly other factors apart from 
lipoprotein levels are important. Likely to be chief among these are the effects of HRT 
on fibrinolysis and endothelial function.
Studies had demonstrated that CRP and IL-6 are increased by HRT [244] [320]. Clinical 
epidemiological studies have also consistently shown that elevated CRP is a risk factor 
for CHD in women. Elevated CRP has been linked to changes in complement and 
induces tissue factors and adhesion molecules. The WHI demonstrated that baseline 
levels of CRP and IL-6 were associated with a 2-fold increase in risk of developing CHD. 
In the WHI HRT was associated with increasing CRP levels but no such change was seen
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in the IL-6 levels, suggesting that the preparation used was not stimulating a generalized 
inflammatory response. In our own study the CRP levels were not altered significantly 
and the IL-6 levels were seen to fall significantly. Cai'e must be taken when interpreting 
this result.
The increase in risk of stroke and CHD in the WHI trial was surprising given that at the 
end of the first year of treatment the LDL-cholesterol had decreased by 12.7% in the 
active treatment group compared to the placebo group. The level of HDL-cholesterol had 
also increased by 7.3% over the same time period in the treatment group compared to the 
placebo group. Similarly in the HERS trial an 11% reduction in LDL-c and an 11 % 
increase in HDL-c was seen. Although the lipid changes aie smaller than those achieved 
by statins if one assumes an almost 2% reduction in CHD for every 1 % decline in LDL- 
cholesterol and an almost 2 to 3% decrease for every 1% rise in HDL-cholesterol then 
there would have been an anticipated fall in primary CHD incidence of between 30 and 
35% and a 24% reduction in CHD incidence based on secondary prevention induced by 
simvastatin [351] [352] (see table 7.1). The lack of effect seen may be as neither of the 
trials was powered to fully detect a significant benefit associated with either LDL-c 
reduction or HDL-c elevation.
• Another secondary prevention of CHD trial has had similar results. The preparation
under investigation in this incidence was bezafibrate, a fibric acid derivative [353]. In 
this study a fall in triglycerides by 21% and a rise in HDL-c of 18% did not significantly 
reduce the overall risk of recurrent cardiovascular events. Although LDL-c reduction and 
HDL-c elevation are established strategies for secondai'y prevention of CHD the clinical 
effect of lipid lowering agents on secondary CHD prevention cannot be predicted solely
I by their effects on lipid levels.
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The effect of bone density was also examined in our study and in the HERS II and WHI 
trials. Significant changes were seen at all sites examined including total hip, Ward’s 
triangle, femoral shaft and trochanter after adjustment for baseline BMD, BMI and years 
since menopause. No change was seen at the neck of femur. Serum bone alkaline 
phosphatase also decreased in the group on active treatment by 23%. The fall seen in the 
control group of this substance over the treatment time period made this result even more 
significant (p<0.001). The HERS II trial reported no decrease in the risk of fracture in 
their treatment group indicated by a lack of increase in BMD [354].
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Table 7.1
Comparing effects in our trial, HRT trials and statin trials.
Trial Ours HERS [241] WHI[234] 4S[83]
No. DM (%) 100 2.7 4.4 4.5
Reduction in LDL-C 13.2 10.9 12.7 35.0
Change in HDL-C -5.4 11.0 7.3 8.0
Change in TG’s -1.9 9.0 6.9 -10.0
Duration of Treatment (yrs). 0.5 4.1 5.2 4
CHD Incidence (RR) na 0.99 1.29 0.67
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The investigators did however indicate that this may have been due to the absence of 
routine spinal radiographs in the trial which would have meant that some vertebral 
fractures would have been missed and also that fewer of the women recruited had 
osteoporosis than would have been expected for a group of women of this age. They 
pointed out that clinical trials of bisphosphonates have found an effect on the risk of 
fracture in women with osteoporosis but not in women with normal bone density [355] 
The WHI is the first trial with definitive data supporting the ability of postmenopausal 
HRT to prevent fractures at the hip, vertebrae and other sites.
The investigation of effects on liver function tests was not a pre-specified end-point of 
our original study but rather a post hoc analysis stimulated by the results of the WHI 
study suggesting a protective effect of HRT on risk for type 2 DM. The results of this 
study suggest HRT containing oestradiol and norethisterone can lessen circulating 
concentrations of liver function tests in women with diabetes possibly by reducing liver 
fat content. Whilst these data do not advocate a role for HRT for this reason, improved 
understanding of the mechanisms for such an effect may lead to new therapies to. treat 
individuals with NAFL.
151
7.4 Future Prospects
The results of our trial would suggest that this low dose preparation could be of benefit in 
the prevention of CHD in postmenopausal studies but the overriding evidence from the 
large randomized controlled trials of HRT with clinical rather than surrogate end points is 
that HRT has no place in the prevention, either primary or secondary, of CHD or indeed 
of stroke in postmenopausal women.
Research into the area of inflammatory indices and their effect on CHD risk is an area of 
expansion at present and any role that HRT may have in their modulation would be of 
interest to our future understanding of the vascular effects of HRT.
Future studies with HRT are unlikely to be conducted but studies of selective estrogen 
receptor modulators (SERMS) e.g. Raloxifene, are ongoing. Selective estrogen receptor 
modulators improve cardiovascular risk factors, reduce the risk of vertebral fracture, and 
are associated with a reduced incidence of invasive breast cancer in postmenopausal 
women with osteoporosis. In the Raloxifene use for the Heart (RUTH) trial 10,101 
postmenopausal women were randomized to receive either 60mg of raloxifene or placebo 
per day. Approximately half of the women had documented coronary heart disease 
(CHD) (n -  5,031); the remainder had multiple CHD risk factors that increased their risk 
for a CHD event (n = 5,070). The RUTH cohort is the largest group of postmenopausal 
women at increased risk of CHD events ever assembled in a clinical trial, and is the first 
trial designed to determine the effect of a selective estrogen receptor modulator on the 
risk of CHD events. The results of this trial are eagerly awaited. [356]
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7.5 Recommendations for the use of HRT.
For menopausal vasomotor symptoms -lowest dose for shortest time possible, consider 
topical preparations
For postmenopausal osteoporosis-use of non oestrogen treatments is recommended e.g. 
bisphosphonates, calcitonin. HRT only recommended when osteoporosis risk outweighs 
the risk of HRT preparation used.
For CHD prevention- HRT has no place here and other methods of reducing CHD should 
be employed e.g. diet and exercise, smoking cessation, control of hypertension, control of 
DM, statin therapy and antiplatelet therapy.
The US Food and Drug Administration (FDA) has recommended that all HRT 
preparations should have a box on the packaging warning of possible harm from HRT to 
include risk of heart disease, heart attack, stroke and breast cancer. The label also has to 
indicate that HRT prepai ations are only recommended for vasomotor symptoms of 
menopause, for vulvovaginal atrophy and for prevention of postmenopausal osteoporosis.
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